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Abstract 
Background – Apelin agonism causes vasodilatation and increased cardiac 
contractility in humans and improves pulmonary arterial hypertension in animal 
models. We here aimed to determine the pulmonary haemodynamic effects of 
apelin in patients with pulmonary arterial hypertension (PAH) and to determine 
the effects of apelin on rat pulmonary artery fibroblasts in the lab. 
 
Methods and Results – In a double-blind randomized crossover study, 19 
patients with PAH received intravenous (Pyr1)apelin-13 (10-100 nmol/min) and 
matched saline placebo during invasive right heart catheterization and 
measurement of pulmonary artery pressure, pulmonary artery wedge pressure, 
cardiac output. Acute (Pyr1)apelin-13 infusion caused a reduction in pulmonary 
vascular resistance (p=0.001), increased cardiac output (p<0.0001) and an 
increase in stroke volume (p<0.0001).  
Apelin also prevented the hypoxic hyperproliferation and migration of rat 
pulmonary artery fibroblasts and reduced the activity of p38 MAP kinase. 
 
Conclusions – Acute intravenous (Pyr1)apelin infusion reduces pulmonary 
vascular resistance and increases cardiac output and stroke volume in patients 
with PAH. It also prevented fibroblast proliferation and migration and reduced 
the activity of the p38 MAP kinase pathway. Apelin agonism is an novel potential 
therapeutic target for the treatment of PAH and appears to improve both the 
haemodynamic consequences of pulmonary hypertension as well as potentially 
improving the remodelling seen in the pulmonary vasculature of patients with 
pulmonary hypertension. 
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1.1 Pulmonary Hypertension 
This thesis focuses on a condition called pulmonary hypertension (PH) which is a 
disease in which functional and structural changes of the pulmonary vasculature 
cause a progressive increase in pulmonary vascular resistance (PVR), leading to 
pressure overload of the right ventricle (RV) and premature death. This is 
thought to arise from an imbalance between vasodilator and vasoconstrictor 
mediators. In addition, structural changes of the vessel walls (remodelling) due 
to proliferation of the endothelium, smooth muscle cells and fibroblasts cause 
progressive obstruction of the pulmonary vascular bed1. There are limited 
therapeutic options based on agents that reduce pulmonary vascular tone. 
Despite recent therapeutic advances, there remains an unacceptably high 3-year 
mortality of around 50%2  and there is an urgent need to develop new effective 
therapies. 
1.1.1 Definition of pulmonary hypertension 
Normal pulmonary artery pressure (PAP) is defined by consensus opinion as a 
resting mean pulmonary artery pressure (mPAP) of ≤ 20 mmHg. Pulmonary 
hypertension is defined by a resting mPAP ≥ 25 mmHg as measured at right heart 
catheterisation3. Pulmonary hypertension can be caused by disease of the 
pulmonary arteries themselves (pulmonary arterial hypertension) or as a 
consequence of elevation of pressure in the pulmonary venous system or 
pulmonary capillaries. Table 1-14 details the haemodynamic definition of 
different classifications of pulmonary hypertension. 
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Definition Characteristics Clinical Groups 
Pulmonary Hypertension 
(PH) 
mPAP ≥ 25 mmHg All 
Pre-capillary PH mPAP ≥ 25 mmHg 
PAWP ≤ 15mmHg 
1. Pulmonary Arterial Hypertension 
3. PH due to lung diseases and/or 
hypoxia 
4. Chronic thromboembolic 
pulmonary hypertension 
5. PH with unclear multifactorial 
mechanisms 
Post-capillary PH mPAP ≥ 25 mmHg 
PAWP > 15 mmHg 
2. PH due to left heart disease 
Table 1-1 Haemodynamic definition of pulmonary hypertension.  
Adapted from “2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary 
hypertension” by Galiè et al. European Heart Journal, 2016, 37, pp 67-119. PH indicates 
pulmonary hypertension; mPAP, mean pulmonary artery pressure; PAWP, pulmonary 
artery wedge pressure. 
 
1.1.2 Clinical classification and epidemiology of pulmonary 
hypertension 
The first World Symposia on Pulmonary Hypertension was organised by the World 
Health Organisation in 1973 after an epidemic of pulmonary arterial 
hypertension (PAH) cases secondary to anorexigens. A simple classification was 
established at this time along with a haemodynamic definition5. This 
classification has developed over the subsequent years in order to categorise PH 
into different subgroups sharing similar pathological findings, haemodynamic 
characteristics and similar management strategies6. The current clinical 
classification divides PH into 5 distinct subgroups as seen in Table 1-26. The 
group that I have concentrated on for the purposes of this thesis is group 1. 
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Updated Classification of Pulmonary Hypertension 
Group 1.Pulmonary arterial hypertension 
1.1 Idiopathic PAH 
1.2 Heritable PAH 
1.2.1 BMPR2 
1.2.2 ALK-1,ENG,SMAD9,CAV1,KCNK3 
1.2.3 Unknown 
1.3 Drug and toxin induced 
1.4Associated with: 
1.4.1 Connective tissue disease 
1.4.2 HIV infection 
1.4.3 Portal hypertension 
1.4.4 Congenital heart diseases 
1.4.5 Schistosomiasis 
1’ Pulmonary veno-occlusive disease and/or pulmonary capillary 
haemangiomatosis 
1’’ Persistent pulmonary hypertension of the newborn (PPHN) 
Group 2. Pulmonary hypertension due to left heart disease 
2.1 Left ventricular systolic dysfunction 
2.2 Left ventricular diastolic dysfunction 
2.3 Valvular disease 
2.4 Congenital/acquired left heart inflow/outflow tract 
obstruction and congenital cardiomyopathies 
Group 3. Pulmonary hypertension due to lung diseases 
and/or hypoxia 
3.1 Chronic obstructive pulmonary disease 
3.2 Interstitial lung disease 
3.3 Other pulmonary diseases with mixed restrictive and 
obstructive pattern 
3.4 Sleep-disordered breathing 
3.5 Alveolar hypoventilation disorders 
3.6 Chronic exposure to high altitude 
3.7 Developmental lung disease 
Group 4. Chronic thromboembolic pulmonary hypertension 
(CTEPH) 
Group 5. Pulmonary hypertension with unclear 
multifactorial mechanisms 
5.1 Haematologic disorders: chronic haemolytic anaemia, 
myeloproliferative disorders, splenectomy 
5.2 Systemic disorders: sarcoidosis, pulmonary histiocytosis, 
lymphangioleiomyomatosis 
5.3 Metabolic disorders: glycogen storage disease, Gaucher 
disease, thyroid disorders 
5.4 Others: tumoural obstruction, fibrosing mediatinitis, chronic 
renal failure, segmental PH 
Table 1-2 Clinical Classification of Pulmonary Hypertension.  
Adapted from “Updated clinical classification of pulmonary hypertension” by  Simonneau et 
al. Journal of the American College of Cardiology, 2013, vol. 62 (25 Suppl) ppD34-41. PAH 
indicates pulmonary arterial hypertension; BMPR2, bone morphogenic protein type 2 
receptor; PPHN, persistant pulmonary hypertension of the newborn; CTEPH, chronic 
thromboembolic pulmonary hypertension. 
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1.1.2.1 Idiopathic pulmonary arterial hypertension 
Group 1 PH is diagnosed at right heart catheterisation based on a mPAP ≥ 25 
mmHg with pulmonary artery wedge pressure (PAWP) < 15mmHg and a normal or 
reduced cardiac output (CO). To fit into this classification group, left heart 
disease, hypoxic lung disease and chronic pulmonary thromboemboli must be 
excluded as causes. In this group the pulmonary hypertension is usually severe 
but it is also a rare cause of pulmonary hypertension. Due to the information 
gathered by several national registries the it is estimated that the incidence of 
PAH is 5-10 cases per million and its prevalence is 15-60 per million4. The 
pathobiological changes described in chapter 1.1.3 lead to a progressive increase 
in pulmonary vascular resistance, which consequently leads to right ventricular 
overload, hypertrophy, dilatation and failure. 
Pulmonary hypertension should be considered in any patient with unexplained 
breathlessness, syncope and/or signs of right ventricular failure.  
The onset of symptoms can be insidious and average time to diagnosis can be up 
to 4 years7. A high index of suspicion is therefore required in order to establish 
diagnosis at an earlier stage. There are specific groups that are considered at 
higher risk of developing pulmonary hypertension and screening programmes 
may be advocated in these groups. This includes patients with connective tissue 
disease, HIV, chronic liver disease and congenital heart disease. 
1.1.2.2 Pulmonary hypertension due to left heart disease 
Pulmonary hypertension due to left heart disease is defined as a mean 
pulmonary artery pressure ≥ 25 mmHg but with a pulmonary artery wedge 
pressure > 15 mmHg (Table 1-1). PH due to left ventricular systolic and diastolic 
dysfunction, valvular heart disease and cardiomyopathies are included in group 2 
PH. PH initially develops due to a proportional increase in pulmonary artery 
systolic pressure which is an adaptation in order to maintain adequate flow 
across the pulmonary vasculature. 
 
Pulmonary hypertension is a common consequence of left heart disease and 
when present is associated with more severe symptoms and poorer exercise 
tolerance8-10. This is probably the most common form of PH11 and in one study of 
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246 elderly patients assessed for PH, only 15% had idiopathic PAH. The most 
frequent diagnosis was group 2 PH – secondary to left heart disease12.  
It can be difficult to differentiate group 2 PH from PAH when these patients 
have preserved ejection fraction. The haemodynamic definition of pulmonary 
hypertension due to left heart disease is based on a mean pulmonary artery 
pressure of ≥ 25 mmHg as measured at right heart catheterisation, a pulmonary 
artery wedge pressure > 15 mmHg and a normal or reduced cardiac output9. The 
patient may need a fluid/exercise challenge to elicit the raised pulmonary artery 
wedge pressure. Usually the transpulmonary gradient is low and as a 
consequence the pulmonary vascular resistance is normal or near normal.  
There is a subset of patients, however, who develop a more severe 
phenotype11,13-17. At right heart catheterisation they are found to have a high 
transpulmonary gradient (> 12mmHg) with a high pulmonary vascular resistance. 
These patients seem to ‘reactively’ develop pulmonary vascular disease with 
remodelling of the pulmonary arteries. In fact, histologically, the pulmonary 
vasculature is no different to patients with PAH17. PH has been found to be an 
independent predictor of mortality in left heart failure10,18,19. 
Pulmonary hypertension due to left heart disease usually initially occurs due to 
backward transmission of filling pressures leading to a stepwise increase in 
venous, capillary and arterial pulmonary system pressures. The left atrial-venous 
pressure rise over time drives an increase in pulmonary artery pressure and 
therefore an increase in the pulsatile loading of the right ventricle leading to 
right ventricular dysfunction and failure20. 
Studies have shown that optimisation of heart failure treatment/surgical 
correction of valvular heart disease can lead to a regression in PH13. This is not 
usually the case in the subset of patients with more severe disease14, and there 
are currently no available therapies which specifically treat the pulmonary 
vasculature and/or right ventricle in left heart disease. With this poorer 
prognosis in mind, several groups have investigated whether targeting the 
pulmonary vasculature with PAH specific therapies could be of benefit in left 
heart disease21-24. Most have been ineffective for treating left heart disease, 
though it should be noted that PH was not part of the inclusion criteria for many 
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of these studies. Sildenafil, however, has shown some potential in recent studies 
with evidence of haemodynamic and exercise improvement as well as fewer 
hospitalisations25-27. The development of new therapies to treat this population 
is urgently required. 
1.1.3 Pathobiology and pathophysiology of pulmonary 
hypertension 
The normal pulmonary circulation consists of thin walled, compliant vessels and 
is typically a high flow, low pressure circuit. This allows minimal changes in 
pressure when there is increased flow through the pulmonary vasculature during 
exercise. In pulmonary hypertension there is increased pulmonary vascular 
resistance which occurs due to a combination of vasoconstriction, vascular wall 
remodelling and thrombosis28.  
Pulmonary vascular wall remodelling involves pathological changes to all three 
layers of the pulmonary artery wall: the adventitia, media and intima and 
involves fibroblasts, smooth muscle cells and endothelial cells. These changes 
include fibroblast and endothelial cell proliferation, smooth muscle cell 
hypertrophy and muscularisation of small pulmonary arterioles, fibrosis as well 
as insitu thrombosis which leads to thickening of the pulmonary artery vessel 
wall and luminal occlusion29. There is an imbalance in vasoactive mediators in 
PAH. Endothelin-1 levels are elevated and are known to be a potent 
vasoconstrictor. Nitric oxide synthase (and hence nitric oxide) expression is 
decreased in PAH, again encouraging vasoconstriction. Prostacyclin has 
vasodilatory and antiproliferative effects and levels are low in PAH again leading 
to vasoconstriction of the pulmonary artery30. The combination of these 
processes leads to an increase in pulmonary vascular resistance. The precise 
cause of these processes are unknown but it is felt certain that the cause of PAH 
is multifactorial with genetic, environmental and inflammatory processes 
working in a “multiple-hit” mechanism31. 
This process of progressive increase in pulmonary vascular resistance leads to 
obstruction to pulmonary blood flow and therefore to an increase in right 
ventricular afterload. There is an initial adaptive response and the right 
ventricle hypertrophies and dilates (Figure 1-1) as it tries to compensate and 
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increase preload and myocardial contractility32. In the face of progressive 
increases in pulmonary vascular resistance, the right ventricle decompensates 
with reduced cardiac output and right ventricular failure. Unchecked this 
process culminates in death. 
 
Figure 1-1 Short axis cardiac MRI.  
Normal heart (left image) and heart of patient with pulmonary hypertension (right image). 
The right ventricle (RV) is bigger in pulmonary hypertension, compressing the left 
ventricle (LV) and causing bowing of the interventricular septum. 
 
1.1.4 Investigation of pulmonary hypertension 
The evaluation of a patient with suspected PH involves a series of investigations, 
which determines to confirm the diagnosis of PH, clarify the classification and 
aetiology and evaluate the severity. Figure 1-2 shows the process of evaluation 
set out by the ESC/ERS guidelines4. Right heart catheterisation is the gold 
standard test in the evaluation of PH and is the only way to accurately measure 
the pulmonary artery pressures. The procedure is safe and well tolerated with a 
mortality of 0.055% and morbidity of 1.1%33. 
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Figure 1-2 Diagnostic algorithm.  
Adapted from “2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary 
hypertension” by Galiè et al. European Heart Journal, 2016, 37, pp 67-119. PH indicates 
pulmonary hypertension; ECG, electrocardiograph; PFT, pulmonary function test; DLCO, 
diffusing capacity of the lung for carbon monoxide; CXR, chest xray; HRCT, high resolution 
computed tomography; ABG, arterial blood gas. 
 
1.1.5 Prognosis 
PH is progressive and fatal if untreated. Historical data shows that untreated the 
median survival in patients with PAH is less than 2 years34. Now that a range of 
therapies are available, patients have improved mortality with a recent UK study 
showing a 5-year survival of 61.1%35.  
A risk assessment strategy (Table 1-3) has been proposed by the ESC/ERS 
guidelines to help provide prognostic information and therefore guide 
therapeutic strategy. The ‘determinants of prognosis’ can be evaluated for each 
patient at diagnosis and at each follow up visit and may help to guide treatment 
escalation if patients are deemed to be progressing poorly. 
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Determinants 
of prognosis 
(estimated 1-
year mortality) 
Low risk <5% Intermediate risk (5-
10%) 
High risk >10% 
Clinical signs of 
right heart failure 
Absent Absent Present 
Progression of 
symptoms 
 
No Slow Rapid 
 
Syncope No Occasional Repeated 
WHO functional 
status 
I,II III IV 
6MWD >440m 165-440m <165m 
NT-proBNP plasma 
levels 
<300 ng/l 300-1400 ng/l >1400 ng/l 
Pericardial 
effusion 
none none/minimal present 
Right Atrial 
Pressure 
<8 mmHg 8-14 mmHg >14 mmHg 
Cardiac Index ≥ 2.5 l/min/m3 2-2.4 l/min/m3 <2 l/min/m3 
Table 1-3 Risk assessment in pulmonary arterial hypertension 
Adapted from “2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary 
hypertension” by Galiè et al. European Heart Journal, 2016, 37, pp 67-119. WHO indicates World 
Health Organisation; 6MWD, 6 minute walk distance; NT proBNP, N-terminal pro b-type natriuretic 
peptide. 
 
1.1.6 Treatment of idiopathic pulmonary arterial hypertension 
There has been some development in the treatment of pulmonary hypertension 
since 1998 when there was only epoprostenol available. The evidence-based 
treatment algorithm recommended at the last World Symposium on pulmonary 
hypertension is summarised in Figure 1-336. 
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Figure 1-3 Treatment algorithm for pulmonary arterial hypertension patients 
Adapted from “2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary 
hypertension” by Galiè et al. European Heart Journal, 2016, 37, pp 67-119. PAH indicates 
pulmonary arterial hypertension; CBB, calcium channel blocker; FC, functional class; IV, 
intravenous. 
 
This algorithm, as well as recommending pharmaceutical treatments also 
recommends a number of general and supportive measures. 
Physical exercise and rehabilitation alone have been shown to improve exercise 
tolerance, quality of life and WHO functional class (severity scoring system)37. 
Supportive treatment in the form of oral anticoagulation, diuretics, oxygen and 
digoxin are also recommended. 
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At diagnosis, patients have pulmonary artery pressure measurements taken at 
baseline and during inhalation of nitric oxide, a potent pulmonary artery 
vasodilator. Patients who have a significant improvement in pulmonary artery 
pressures in response are so-called vasoreactive. They have a significant benefit 
in prognosis compared with those who do not respond and do well on treatment 
with high dose calcium channel blockers. 
Drugs which specifically treat pulmonary arterial hypertension act on three 
distinct pathways in the pulmonary circulation. The endothelin (endothelin 
receptor antagonists), the nitric oxide pathway (soluble guanylate cyclase 
stimulators, phosphodiesterase 5 inhibitors) and the prostacyclin pathway 
(prostanoids). Principally these drugs work by causing vasodilation through 
relaxation of the smooth muscle cells in the pulmonary artery. This therefore 
allows improvement of blood flow through the pulmonary vasculature and 
reduces right ventricular overload but there is little evidence that there is any 
reversal of the pulmonary vascular remodelling seen in pulmonary arterial 
hypertension. 
Of the number of drugs recommended in the algorithm only two have been 
shown in clinical studies to provide clear morbidity and mortality benefit; 
epoprostenol38 and macitentan39. The other pulmonary arterial hypertension 
specific drugs demonstrated improvements in exercise capacity, functional class 
and haemodynamics but did not look at morbidity and mortality. 
Initial choice in drug therapy is based on a number of factors including disease 
severity, patient preference and comorbidity. In general patients are started on 
a single agent although in those with more severe disease at diagnosis, 
combination therapy is possible. Patient response to treatment is assessed at 
intervals by exercise capacity (six minute walk test), WHO functional class etc. 
When the response is inadequate then other pulmonary arterial hypertension 
specific agents can be added. 
Other possible interventions include lung transplantation and balloon atrial 
septostomy. Lung transplantation is reserved for when patients have an 
inadequate response to maximal combination treatment. Balloon atrial 
septostomy is a procedure in which a hole is created in the septum between the 
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right and left atria causing a right to left shunt and therefore reduces right 
ventricular overload and can improve left ventricle preload and cardiac output. 
As a consequence the shunt can cause hypoxaemia and as such is not 
recommended in patients with O2 saturations of <85%. It can lead to significant 
symptom improvement particularly in those with refractory right ventricular 
failure and syncope and so can be useful for palliation or as a bridge to 
definitive treatment such as transplantation. 
1.2 Apelin 
1.2.1 The history of apelin in cardiovascular disease 
Almost all the known peptide hormones/neuropeptides exert their biological 
activity by acting on G protein coupled receptors (GPCRs). The APJ receptor was 
first identified in 1993 via the human genome project; an international scientific 
research project with the goal of DNA sequencing. Genome research unveiled a 
total of about 300 GPCRs of which 160 had ligands. The rest had no known ligand 
and are described as orphan receptors40. Apelin was first discovered in 1998 and 
is the endogenous ligand for the previously orphaned GPCR, APJ41. Tatemoto et 
al isolated the ligand from bovine tissue and named it apelin (APj Endogenous 
LIgaNd)41. APJ itself most closely identified with angiotensin (AT1) receptor 
sharing 54% homolgy42 but angiotensin II was unable to activate the receptor. 
The apelin gene encodes a 77-amino acid peptide (Apelin-36). Shorter C-terminal 
fragments of apelin-36 have also been detected, including the pyroglutamated 
form of apelin-13, (Pyr1)apelin-13, which exhibits greater affinity for the APJ 
receptor and may represent the principal endogenous ligand43.  
Apelin and APJ receptor mRNA is expressed extensively in body tissue. The 
highest expression appears to be vascular tissue44. APJ receptors have been 
found to be present on vascular endothelial cells, vascular smooth muscle cells, 
and cardiomyocytes45. This has lead to studies of its significance in the 
cardiovascular system. Human studies have also shown apelin to be present in 
pulmonary arteries46. 
In preclinical models, apelin signalling exerts major effects on both vascular 
tone and cardiac contractility. In ex vivo myography studies, apelin causes 
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vascular tone to be reduced by up to 50% in both systemic arteries47,48 and 
veins49. This response is attenuated by inhibition of nitric oxide (NO) but not by 
inhibition of prostacyclin48 suggesting a mechanism of action via the NO 
pathway.  In isolated rat hearts, apelin is the most potent endogenous inotrope 
described so far40.  
In rodents, apelin also increases cardiac contractility in vivo and causes a rapid 
fall in both arterial blood pressure and systemic venous tone, with corresponding 
reductions in left ventricular afterload and preload50-53. This effect was 
prevented in Rodents treated with L-NAME (nitric oxide synthase inhibitor)51 
again supporting a mechanism of action via the NO pathway. 
Apelin-deficient mice develop premature heart failure unless plasma apelin 
concentrations are restored54. Reductions in myocardial apelin and APJ 
expression have also been demonstrated in experimental rodent models of heart 
failure40. Despite the apparent down regulation of apelin-APJ activity, the 
haemodynamic effects of exogenous apelin are maintained or even augmented in 
rodents with heart failure55.  
Failing human hearts also exhibit altered patterns of Apelin and APJ gene 
expression, and plasma apelin concentrations appear to be markedly reduced in 
patients with severe chronic heart failure56. Following mechanical offloading of 
the heart with left ventricular assist devices the APJ expression increases57 This 
has excited interest in the apelin-APJ pathway as a target for therapeutic 
intervention in this condition.  
Professor Newby, with whom I collaborated in this study, and his team at The 
University of Edinburgh Centre of Cardiovascular Science recently provided the 
first evidence that apelin has vasoactive actions in humans. They have shown 
that apelin causes vasodilatation in vivo in the human forearm circulation of 
healthy volunteers through predominantly nitric oxide–dependent mechanisms, 
and that this effect is preserved in patients with heart failure58,59. Furthermore, 
apelin is a direct coronary vasodilator and increases myocardial contractility in 
humans. It causes a reduction in both peak and end-diastolic left ventricular 
pressures59.  
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In addition they have recently assessed the effect of prolonged systemic infusion 
of apelin in man60. During 6-hour infusions the inotropic actions of apelin were 
maintained. Furthermore, they monitored pulmonary artery blood flow during 
the first hour of apelin infusion using echocardiography and found this to be 
increased with apelin infusion versus saline placebo.  
In all of human studies apelin was well tolerated with no serious adverse events 
or ECG changes.  
1.2.2 Pulmonary arterial hypertension and the role of apelin 
Mutations in the bone morphogenetic protein receptor (BMPR)2 gene which 
encodes the cell receptor BMPR-II are found in 25% of sporadic and up to 80% of 
familial forms of idiopathic PAH (IPAH)61. Dysfunction of BMP signalling is linked 
to the pathogenesis of PAH. Patients with PAH demonstrate reduced expression 
of BMPR-II in their lungs whether they have BMPR2 gene mutation or not62. 
Reduced BMPR2 signalling promotes apoptosis of pulmonary artery endothelial 
cells (PAEC) and reduced endothelial cell survival may underlie the loss of 
microvessels, both in human disease as well as in animal models of PAH63. 
BMPR2-mediated signalling recruits the Wingless/beta-catenin (Wnt/βC) pathway 
to mediate expression of genes that promote PAEC survival, proliferation and 
angiogenesis64. BMP-2, a natural ligand for BMPR-II, mediates PAEC survival 
through the formation of a nuclear complex between PPARγ and βC. Inhibition of 
PPARγ and hence inhibition of the formation of this complex impairs PAEC 
survival. By using ChIP-chip in combination with whole genome wide gene-
expression microarrays, the apelin gene was identified as one of a number of 
transcriptional targets of the PPARγ–βC complex65. Therefore apelin is a product 
of BMPR2 signalling and its production can be affected by dysfunction of this 
signalling pathway.  
The highest level of apelin mRNA tissue expression is in the lung and this is 
thought to be the predominant source of circulating Apelin44. Immuno-staining 
techniques demonstrate distinct apelin staining within human vascular 
endothelium45. The expression of apelin is reduced in the PAEC of patients with 
IPAH compared with donor control lungs65. Reducing apelin in PAEC by siRNA 
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impairs PAEC survival and promotes pulmonary artery smooth muscle cell 
proliferation65. Furthermore, apelin can directly suppress vascular smooth 
muscle cell proliferation in response to growth factors, and is pro-apoptotic65. 
Plasma apelin-36 concentrations are also reduced in patients with IPAH46. The 
combination of raised plasma NT proBNP concentrations and reduced plasma 
apelin concentrations has been proposed as a prognostic biomarker for PAH. 
Consistent with these observations, TIE2CrePPARγflox/flox mice, a murine model in 
which PPARγ is selectively deleted in endothelial cells, show reduced apelin 
mRNA and protein expression in lungs and PAEC, and exhibit increased 
pulmonary arterial muscularisation, increased right ventricular systolic pressure 
and right ventricular hypertrophy consistent with PAH. A two-week course of 
treatment with apelin significantly reversed these signs of PAH in this murine 
model65. 
An apelin-null murine model was developed and exposed to chronic hypoxia 
which is well known to establish PH in wild-type mice. The apelin-null mice were 
found to develop a more severe phenotype of PH when compared to the wild-
type mice kept in the same conditions66. They had comparatively higher right 
ventricular systolic pressures (RVSP) and increased muscularisation of the 
arterial walls. There was no difference in systolic blood pressure between the 2 
groups67. Serum nitrate levels were also measured as a surrogate for NO and the 
apelin-null mice demonstrated significantly lower nitrate levels66 which was 
secondary to down-regulation of endothelial nitric oxide synthase (eNOS)66, 
again signifying that the NO pathway plays an important role in apelin signalling. 
Another model of PH is the monacrotaline rat. A prevention study in which 
rodents were injected with monacrotaline, and then randomised to receive 
(Pyr1)apelin-13 versus placebo, showed that apelin prevented the 
downregulation of RV apelin and APJ expression as well as preventing the 
haemodynamic changes seen in pulmonary hypertension and the right ventricular 
hypertrophy68.  
Patients with idiopathic pulmonary arterial hypertension have been shown to 
have reduced plasma apelin levels when compared with controls46,65,66. However 
in chronic hypoxic rats it has been shown that apelin plasma levels did not 
Chapter 1  30 
 
correlate with the apelin content in lung or with right ventricular systolic 
pressure69. 
The precise physiological role of apelin, and hence the consequences of reduced 
plasma concentrations in PAH and left heart disease are unknown.  Given the 
biological properties of apelin and the data from heart failure studies, it is 
reasonable to suppose that reduced apelin activity contributes to the pathology 
of these diseases. Consequently I hypothesis that APJ receptor agonism with 
apelin would benefit patients with PAH by reducing pulmonary vascular 
resistance and increasing cardiac output. In doing so apelin may have a role in 
the treatment of left heart disease with associated PH.  
1.3 The aims and hypothesis 
In healthy volunteers and patients with heart failure, it has been demonstrated 
that systemic intravenous apelin infusions increased cardiac index and lowered 
mean arterial pressure and peripheral vascular resistance. However, to date, 
there are no data on the effect of apelin on central filling pressures and 
specifically the vasomotor effects on the pulmonary circulation. My aim was to 
examine the effects of intravenous apelin administration on the pulmonary 
haemodynamics of patients with pulmonary arterial hypertension (PAH) which is 
idiopathic, heritable or associated with connective tissue disease (CTD) or 
drugs/toxins (group 1)70. The study was done in collaboration with Professor 
Newby from the university of Edinburgh Centre of Cardiovascular Science who’s 
role it was to investigate the effects of Apelin in patients with pulmonary 
hypertension associated with left heart disease (group 2) and normal healthy 
controls. 
It was also my aim to study the effects of apelin in the pulmonary circulation, in 
particular to see what effects it would have on pulmonary artery fibroblasts and 
see if apelin can reduce the proliferation of these cells seen with hypoxic stress. 
My hypothesis was that apelin would: 
i. Cause pulmonary arterial vasodilation, reduce pulmonary vascular 
resistance and increase cardiac output. 
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ii. Have greater haemodynamic effects in people with pulmonary 
hypertension, especially PAH, than in people with normal pulmonary 
circulation. 
iii. Have antiproliferative effects on pulmonary artery fibroblasts. 
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2 Materials and Methods
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2.1 Clinical study 
2.1.1 Study design 
This was an investigational double-blind randomised crossover trial to investigate 
the acute pulmonary haemodynamic effects of apelin in patients with group 1 
pulmonary arterial hypertension (PAH) and pulmonary hypertension (PH) 
associated with left heart disease. This was set up as a multisite trial and 
recruitment was carried out at the Scottish Pulmonary Vascular Unit (SPVU) at 
The Golden Jubilee National Hospital (GJNH) in Glasgow, The National 
Pulmonary Hypertension Service at Hammersmith Hospital in London and The 
University of Edinburgh Centre of Cardiovascular Science at The Royal Infirmary 
of Edinburgh. Prior to commencement of the trial I wrote the study protocol, 
submitted to the West of Scotland Research and Ethics committee for approval 
and applied for a funding grant from the British Heart Foundation. 
2.1.2 Study populations 
We recruited three populations of patient in order to determine the potential 
differential effects of intravenous apelin on pulmonary arterial haemodynamic 
parameters: 
a) patients with PAH 
b) patients with chronic left heart failure and associated PH 
c) normal healthy controls 
2.1.2.1 Pulmonary arterial hypertension 
Patients with PAH were recruited from the Golden Jubilee National Hospital in 
Glasgow and Hammersmith Hospital in London, both of which are specialised 
national centres for the management of patients with pulmonary arterial 
hypertension. As this was an invasive study being carried out in patients with a 
rare disease, we felt that optimising recruitment potential by involving 2 sites 
was necessary to realistically meet our calculated sample size. 
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Participants recruited for the study were either new patients attending for 
diagnostic work up (which includes right heart catheterisation) or patients with 
known PAH who have been receiving stable doses of approved mono- or 
combination PAH therapy for 2 months prior to the study. 
Inclusion criteria: 
a) PAH that is idiopathic, associated with drugs/toxins, associated with 
connective tissue disease or heritable (group 1 PAH) 
b) mean pulmonary artery pressure ≥ 25 mmHg, pulmonary capillary wedge 
pressure ≤ 15 mmHg and a normal or reduced cardiac output 
c) stable WHO functional capacity of grade II to IV for 3 months prior to 
study 
Exclusion criteria: 
a) significant left ventricular dysfunction 
b) chronic lung disease (FEV1/FVC < 60%; abnormal lungs on computed 
tomography) 
c) chronic thromboembolic pulmonary hypertension 
d) bleeding diathesis 
e) women of child bearing potential 
f) systolic blood pressure >190 mmHg or <100 mmHg 
g) malignant arrhythmia 
h) renal or hepatic failure 
i) haemodynamically significant valvular heart disease 
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j) severe or significant co-morbidity 
2.1.2.2 Pulmonary hypertension associated with left heart disease 
Patients with PH associated with left heart disease were recruited from the 
GJNH in Glasgow and the Royal Infirmary of Edinburgh. The GJNH is home to the 
Scottish National Advanced Heart Failure Service and we were working in 
collaboration with Professor David Newby of the Royal Infirmary of Edinburgh 
who has carried out previous systemic apelin studies in patients with heart 
failure. The results of these studies are not available in this thesis. 
Participants recruited for the study were either hospital admissions undergoing 
assessment of their heart failure or recruited from the outpatient clinic. 
Inclusion criteria: 
a) Stable NYHA grade II to IV heart failure due to left ventricular systolic 
dysfunction 
b) maintained on maximally tolerated doses of ACE inhibitor and beta-
blocker for at least 3 months prior to the study 
c) baseline echocardiography ejection fraction <35%, left ventricular end 
diastolic diameter >5.5cm, shortening fraction <20% and tricuspid 
regurgitant velocity ≥ 3.0 m/s 
Exclusion criteria 
a) bleeding diathesis 
b) women of child bearing potential 
c) systolic blood pressure >190 mmHg or <100 mmHg 
d) malignant arrhythmia 
e) renal or hepatic failure 
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f) haemodynamically significant valvular heart disease 
g) severe or significant co-morbidity 
2.1.2.3 Healthy control subjects 
Healthy control subjects were recruited at the Royal Infirmary of Edinburgh. 
They were identified from patients attending for elective cardiac catheterisation 
with atypical chest pain and who were found not to have obstructive coronary 
artery disease (<50% luminal stenosis) 
Inclusion criteria: 
a) baseline echocardiography pulmonary artery systolic pressure <25 mmHg 
(tricuspid regurgitant velocity <2.5 m/s) confirmed at time of invasive 
right heart catheterisation 
Exclusion criteria: 
a) bleeding diathesis 
b) women of child bearing potential 
c) systolic blood pressure >190 mmHg or <100 mmHg 
d) malignant arrhythmia 
e) renal or hepatic failure 
f) haemodynamically significant valvular heart disease 
g) severe or significant co-morbidity 
2.1.3 Consent 
If the subject met all the inclusion criteria they were offered participation into 
the trial. They were given a patient information sheet (Appendix A) and allowed 
at least 24 hours to consider the information prior to consent being obtained.  
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2.1.4 Drug 
The effects of APJ agonism were determined using synthetic-grade (Pyr1)apelin-
13 (Clinalfa AG, Laufelfingen, Switzerland) 58,59. The apelin was stored at -20°C 
until ready to use. It was administered after dissolution in 0.9% physiological 
saline under aseptic conditions on the day of the study. Doses were chosen based 
on previous systemic human studies carried out by Professor Newby’s team 
based at Royal Infirmary of Edinburgh58-60.  
Drug prescription, preparation and accountability documents were prepared 
(Appendix B). 
2.1.5 Study conditions 
All subjects were fasted for at least 4 hours prior to the procedure and avoided 
alcohol and caffeine for 24 hours prior to the study. The participants also 
delayed taking their routine medication on the morning of the right heart 
catheterisation until completion of the study protocol. Each study was carried 
out in an appropriate investigation room at the designated centre. The rooms 
were quiet and temperature-controlled with subjects in the supine position. 
2.1.6 Study protocol 
All haemodynamic measurements were made with the mid-axillary point used as 
the 0 mmHg reference point. Throughout the study there was continual 
monitoring of heart rate, electrocardiogram, pulse oximetry and every 5 to 15 
minutes systemic arterial blood pressure was measured by automatic cuff 
inflation. 
An 8F introducer sheath (Figure 2-1, Medtronic, USA) was placed in the right 
internal jugular vein using ultrasound imaging or brachial vein using standard 
aseptic techniques.  
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Figure 2-1 Medtronic introducer sheath 
 
A 7F, 2 lumen thermodilution, pressure-measuring tipped Swan-Ganz catheter 
(Figure 2-2, Edwards Lifesciences, USA) was passed with the aid of fluoroscopy 
and pressure tracings (which are characteristic at each site) through the right 
atrium of the heart into the right ventricle and subsequently into the pulmonary 
artery. 
 
Figure 2-2 Swan-Ganz catheter 
 
All centres had a universal data collection document to try and ensure universal 
standards between the sites (Appendix C). 
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2.1.6.1 Pulmonary haemodynamic measurements 
Pulmonary haemodynamic measurements were made by invasive right heart 
catheterisation, which is the gold standard technique. All centres involved were 
experienced at carrying out cardiac catheterisation and there is low morbidity 
and mortality associated with this procedure in experienced hands (1.1% and 
0.055% respectively33). The baseline measurements taken initially included right 
atrial pressure, right ventricular pressure, pulmonary artery pressure (systolic, 
diastolic and mean) and pulmonary arterial wedge pressure. Figure 2-3 shows a 
schematic representation of the study protocol. 
 
Figure 2-3 Schematic of study protocol 
iNO indicates inhaled nitric oxide; RHC, right heart catheterisation; NO, nitric oxide. 
 
Cardiac output was measured by either thermodilution (Glasgow/Edinburgh) or 
the Fick method (London). Both methods of measuring cardiac output are well 
accepted and validated and there should be no consequence for the validity of 
the results of the study by using 2 different techniques because the 
measurements were all within subject comparison. 
Thermodilution cardiac output was determined by injecting a known quantity of 
cold (temperature measured) physiological saline through a proximal port (port 1 
in Figure 2-2) in the Swan-Ganz into the right atrium. A more distal port (port 3 
in Figure 2-2) has a thermistor attached and as the cooler fluid travels from the 
right atrium to the proximal end of the catheter, a brief drop in temperature is 
recorded. This data is used to plot a thermodilution curve and consequentially 
cardiac output can be calculated. 
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Figure 2-4 Swan-Ganz catheter ports 
 
The Fick method determined cardiac output by arterial blood sampling and 
sampling of mixed venous blood from the pulmonary artery via the Swan-Ganz 
catheter. Oxygen consumption was measured using the Fitmate (Cosmed, Italy). 
The cardiac output was then calculated using the modified Fick equation 
(Equation 2-1):  
𝐶𝐶𝐶𝐶 = 𝐶𝐶𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂 𝐶𝐶𝐶𝐶𝑂𝑂𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑂𝑂(O2 content of arterial blood –  O2 content of mixed venous blood) 
Equation 2-1 
CO indicates cardiac output; O2, oxygen.  
 
Pulmonary Vascular resistance was calculated by dividing the difference 
between the mean pulmonary artery and pulmonary arterial wedge pressures by 
the cardiac output (Equation 2-2): 
𝑃𝑃𝑃𝑃𝑃𝑃 = 𝐶𝐶𝑃𝑃𝑚𝑚𝑃𝑃 − 𝑃𝑃𝑚𝑚𝑃𝑃𝑃𝑃
𝐶𝐶𝐶𝐶
 
Equation 2-2 
PVR indicates pulmonary vascular resistance; mPAP, mean pulmonary artery pressure; PAWP, 
pulmonary artery wedge pressure; CO, cardiac output. 
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Systemic vascular resistance (SVR) was calculated by dividing the difference 
between mean arterial pressure and mean right atrial pressure by cardiac output 
(Equation 2-3). SVR was chosen for analysis as we were interested in the 
vasodilatory effects of apelin whether they be pulmonary or systemic. Mean 
arterial pressure was considered for analysis but is dependent on SVR and 
cardiac output (CO) so any change in this variable could not be put down to any 
vasomotor change in the vasculature: 
𝑆𝑆𝑃𝑃𝑃𝑃 = 𝑀𝑀𝑚𝑚𝑃𝑃 −𝐶𝐶𝑃𝑃𝑚𝑚𝑃𝑃
𝐶𝐶𝐶𝐶
 
Equation 2-3 
SVR indicates systemic vascular resistance; MAP, mean arterial pressure; mRAP, mean right atrial 
pressure; CO, cardiac output. 
 
At rest each participant received, in a double-blinded randomised manner, three 
5-minute intravenous infusions of apelin at 10, 30 and 100 nmol/min and three 
5-minute intravenous infusions of saline placebo. Haemodynamic data was 
collected at the end of each 5-minute infusion. Following each 15-minute 
infusion period, if the participant was functionally capable they underwent an 
exercise protocol during which the 100 nmol/min infusion and saline placebo 
during crossover was continued. 
 
To ensure uniformity across the different sites I produced an apelin manual 
(appendix D) which provides a step-by-step breakdown of how to run the study. 
2.1.6.2 Exercise pulmonary haemodynamic measurements 
Patients with PAH are usually asymptomatic at rest and develop symptoms of 
breathlessness when active. We therefore felt it would be interesting to study 
the acute haemodynamic effects of apelin during exercise as well as at rest.  
In order to do this, in the days prior to the right heart catheterisation, subjects 
underwent a progressive incremental cardiopulmonary exercise test (CPET) on 
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an ergometer. Starting at 0 watts (W) for 3 minutes and adding 10W every 
minute until the symptom limited maximum was reached. The purpose of the 
incremental exercise test was to determine the maximal exercise capacity. This 
was used to calculate the exercise work rates for individuals during the exercise 
component of the study. Not all participants had the functional capacity to do 
this and therefore they underwent the resting component of the study only. 
The exercise study was carried out in the supine position with a cycle ergometer 
secured to the catheterisation table (Figure 2-5). 
 
Figure 2-5 Lode Corvial Supine Ergometer with cardiac stress table 
 
Haemodynamic data was first collected with the participants feet strapped into 
the pedals but before the participant begins to cycle. This is because the raising 
of the participants legs alone would increase venous return to the heart and may 
alter pulmonary haemodynamics in itself. The participant was then instructed to 
start turning the pedals at a rate of 60 rotations per minute (rpm) while the 
workload was increased to 20% of the previously determined maximal erect CPET 
workload (Figure 2-6). After 2 minutes of cycling further haemodynamic data 
was collected (while the participant continues to cycle). The workload was then 
increased to 40% of the previously determined maximal erect CPET workload and 
after an additional 2 minutes of cycling further haemodynamic data was 
collected.  
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Figure 2-6 Subject carrying out the exercise protocol 
 
A 30 minute washout/rest period was then carried out before the protocol was 
repeated for the second infusion (Figure 2-3). 
2.1.7 Radiation materials 
As the study involved right heart catheterisation which is carried out with 
fluoroscopy screening (Figure 2-7), details of the ionising radiation exposure had 
to be provided to the research and ethics committee with risks explained to the 
patient in the patient information study. I had to ask a local lead Medical Physics 
Expert to prepare a report detailing the possible ionising radiation exposure 
(Appendix E). 
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Figure 2-7 Fluoroscopy of right heart catheterisation procedure 
Red arrow indicates tip of swann ganz in right main pulmonary artery. 
 
The two possible procedures that subjects participating in the trial may undergo 
would be: 
1. Right heart catheterisation with fluoroscopy screening. 
All subjects recruited will undergo this procedure with an estimated procedure 
dose of 2.1 mSv. This equates to an additional lifetime fatal cancer risk of 1 in 
9600 which is the equivalent of less than 1 years background radiation exposure. 
2. Coronary angiogram with fluoroscopy screening.  
The healthy controls may be recruited when undergoing a coronary angiogram 
for diagnostic reasons. The coronary angiogram was NOT part of the study 
protocol but was included so that total effective dose was known. This exposure 
was likely to affect up to one third of the patients recruited. This procedure 
provided an estimated procedure dose of 5.7 mSv or 7.8 mSv for coronary 
angiogram + right heart catheterisation. A 7.8 mSv effective dose equates to an 
additional lifetime fatal cancer risk of 1 in 2560. 
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2.1.8 Randomisation 
All study participants were allocated an individual study number when recruited. 
Each study number had been randomly allocated an infusion order prior to 
commencement of the study. They were allocated to either receive apelin as 
infusion A then saline placebo as infusion B or vice versa. There was one contact 
who allocated the study number and randomisation order for recruits at all sites 
and a delegate from each site prepared the apelin and saline infusions, labelling 
them infusion A or B as per the randomisation order so that the delegates 
carrying out the study remain blinded. 
2.1.9 Adverse event reporting 
An adverse event is any untoward medical occurrence in a patient or clinical 
investigation subject administered a pharmaceutical product and which does not 
necessarily have a causal relationship with this treatment. An adverse event can 
therefore be any unfavourable and unintended sign (including an abnormal 
finding, for example), symptom, or disease temporally associated with the use 
of a medicinal product, whether or not considered related to the medicinal 
product. 
A serious adverse event is any untoward occurrence that: 
a) results in death 
b) is life-threatening 
c) requires hospitalisation or prolongation of existing hospitalisation 
d) results in persistent or significant disability or incapacity 
e) consists of a congenital anomaly or birth defect 
f) is otherwise considered medically significant by the investigator 
Possible adverse events: 
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Apelin: 
a) A change in mean arterial blood pressure of more than 30 mmHg on two 
consecutive measurements 
b) A change in heart rate of more than 30 beats per minute (bpm) during 
resting data collection on two consecutive measurements 
c) Electrocardiograph (ECG) abnormalities: 
a. second or third degree heart block 
b. sustained bradycardia (<40bpm) or tachycardia (120bpm) 
c. new atrial fibrillation 
d. atrial or ventricular bigeminy 
e. ST segment shift 
f. new T wave inversion or bundle branch block 
d) Discomfort of the study participant 
e) Request of the study participant 
Right heart catheterisation: 
a) Temporary pain/discomfort/bleeding/bruising at catheter insertion site 
b) bleeding 
c) infection 
d) heart rhythm changes 
e) vascular damage 
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f) damage to heart valves 
g) pneumothorax 
h) rarely death 
Fluoroscopy (x-ray) during the right heart catheterisation: 
Minimal amount of exposure to radiation. The typical radiation dose 
during right heart catheterisation is 2.1 mSv. The effective dose is 
equivalent to 11 months background radiation and represents an 
additional risk of lifetime fatal cancer of 1 in 9600. In terms of 
comparative lifetime risk of death, it is similar to the lifetime risk of 
death from work in a service industry, and is in the Intermediate risk 
category for bio-medical research. 
Exercise testing: 
Very low risk of harm. Occasionally causes sore muscles and/or 
breathlessness due to the effort involved. 
Blood drawing: 
a) temporary pain/discomfort from needle stick 
b) tenderness 
c) redness 
d) swelling 
e) bruising 
f) rarely infection 
g) rarely bleeding 
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h) rarely light-headedness 
i) rarely fainting 
j) rarely dizziness 
Any adverse event which occurred should have been documented in the 
participants health records and on an adverse event reporting form (Appendix F) 
which should be sent to the chief investigator and all adverse events were to be 
reviewed and reported in the annual report to the West of Scotland Research 
and Ethics committee/sponsor. 
All serious adverse events were to be recorded in the participants health 
records. Serious adverse events were to be reported to the chief investigator 
within 24 hours of occurrence. The serious adverse event would then be 
analysed as to whether it was related to study procedures and if expected or 
unexpected. All related unexpected events would have been documented on an 
NRES ‘report of serious adverse event’ form and sent to the West of Scotland 
Research and Ethics committee within 15 days of the event. 
2.1.10 Ethical review 
This study was classed as a Clinical Trial of Investigational Medicinal Products 
(CTIMP) and required approval from the West of Scotland Research and Ethics 
Committee before recruitment could go ahead. Initial application prompted a 
reply asking for changes to be made to Patient Information sheets and consent 
forms. Once these changes were made and the documents were resubmitted a 
favourable outcome was achieved. 
A couple of minor amendments were made and approved but there were 2 more 
substantial amendments made at the start of study recruitment.  
The first was regarding the dosing of apelin. Initially we had chosen apelin doses 
of 30 nmol/min, 100 nmol/min and 300 nmol/min which was the doses used in 
the original studies carried out by Professor Newby in Edinburgh. This was used 
during the first subject recruited and the unblinded data showed that there was 
a difference in PVR and Cardiac output (CO) between infusion A and infusion B at 
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30 nmol/min and 100 nmol/min but that the effect was lost at the higher dose 
of 300 nmol/min (Figure 2-8). On reviewing the published data from Japp et al59, 
they had seen a similar plateau effect at 300 nmol/min (Figure 2-9). Based on 
this information we believed that a maximal infusion concentration of apelin at 
100 nmol/min would be enough to expose the physiological actions of apelin on 
the pulmonary vasculature. This amendment was accepted by the West of 
Scotland Research and Ethics committee. 
 
Figure 2-8 Initial study showing percentage change from baseline in cardiac output during 
infusion A and Infusion B. 
 
 
Figure 2-9 Percentage change from baseline in cardiac index (top) and peripheral vascular 
resistance (bottom) with apelin infusion in patients with chronic heart failure (open squares) 
and matched control subjects (closed circles). 
 
A further substantial amendment was required regarding consent for patients 
stopping warfarin. In the initial protocol submission I had not considered that 
because of logistical reasons, patients may have to stop warfarin which they may 
be on for PAH or atrial fibrillation prior to signing the written consent form. In 
50 
 
some cases patients were being recruited for the study from some distance away 
meaning multiple attendances to the recruitment site were impossible and 
inconvenient for the patient. In some occasions the study protocol was discussed 
over the phone and the patient information sheet was sent to them by mail. If 
they then wished to participate in the study they could possibly attend the site 
specifically to take part in the trial and sign the consent within 24 hours of the 
study taking place meaning they may have to stop their warfarin in advance 
prior to signing written consent. The question we asked the ethics committee 
was whether we could take verbal consent for this over the phone when 
circumstances made it easier for the patient. They came back to me with a few 
questions detailed below before responding with a favourable outcome. 
The specific questions I had to answer regarding this amendment were: 
1. ‘The study team should check to establish the reasons patients are on 
warfarin and not assume that they are on this medication because of 
Pulmonary Arterial Hypertension (PAH)’: 
We would never make assumptions about why a patient is on warfarin and when 
they have been identified as a potential recruit for the study in clinic, they are 
screened to make sure they meet the inclusion and exclusion criteria. Significant 
co-morbidity is part of the exclusion criteria. Their past medical history is 
reviewed at this point and any other reason for being on warfarin will be 
identified. We also take the patient through the patient information sheet at 
this time, which in the new version includes a paragraph about warfarin, the 
reasons for stopping it and the risks this may entail. 
2. ‘If patients are established to taking warfarin for reasons other than 
PAH, then it is suggested that they should not be included in the study. If 
the patient is taking warfarin for PAH then the risks of coming off 
warfarin should be fully explained in the Patient Information Sheet (PIS), 
namely the risk of stroke or peripheral embolism’: 
As stated in the Project Protocol version 4, any patients who are on warfarin for 
essential reasons, such as mechanical prosthetic valves, pulmonary embolism or 
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chronic thromboembolic pulmonary hypertension will not be included in the 
study.  
PAH group 
The European Respiratory Society (ERS) Guidelines for the management of 
pulmonary hypertension advise supportive therapy with warfarin in the absence 
of contraindication71. Their reasons for this are based on post-mortem studies in 
patients with IPAH, showing a high prevalence of vascular thrombotic lesions in 
the lungs. The theory is that warfarin prevents these lesions from developing 
and thereby helps to stabilise pulmonary vascular resistance. The guidelines also 
state that there is a “possible presence of non-specific risk factors for venous 
thromboembolism, including heart failure and immobility” and so there is a 
rationale for warfarin as thromboprophylaxis. The target for INR varies around 
the world, in Europe we aim for the standard target of 2-3, whereas in North 
America they aim for 1.5 – 2.5 in most centres. The ERS guidelines quote two 
retrospective, single centre studies as reason for their recommendation; Rich et 
al were assessing the effect of high dose calcium channel blockers on patients 
with IPAH. They carried out a lung scan on the patients and if the scan revealed 
nonuniformity of pulmonary blood flow, they were treated with anticoagulant 
therapy. Patients had additional supportive treatments added depending on 
their other signs and symptoms. Survival was found to be better at 1 year in the 
warfarin treated group than the group not treated with warfarin72. The study 
was not designed to assess the influence of anticoagulation and the authors 
suggest that the results be interpreted with caution as the group treated with 
warfarin may represent a subgroup with greater likelihood of survival. The 
second paper was the postmortem study by Fuster et al. Again this study was 
retrospective and not designed to look at the effects of anticoagulation, but 
there did appear to be a survival advantage in the group treated with warfarin 
though the numbers were small and didn’t reach statistical significance34. A 
qualitative systemic review of 7 small retrospective observational studies 
evaluating the effectiveness of warfarin in PAH found that 5 studies supported 
the effectiveness of anticoagulation therapy in PAH with regards to survival, 
whereas 2 did not73. They conclude that a randomised controlled trial is needed 
to definitively address this important clinical issue. To date, an randomised 
control trial (RCT) has yet to be carried out. There is no data regarding the risk 
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of stroke or peripheral embolism in patients with PAH. The reason behind 
starting warfarin is that there is a possible long term survival advantage to those 
on warfarin. This is explained to patients when they are diagnosed and will be 
made clear to them again in the PIS.  
In summary the evidence base for anticoagulation in PAH is historical and not 
based on validated RCT. Therefore it is difficult to quantify any risk the patient 
may have off this treatment. The rationale is based on the theory that due to 
slower blood flow in the pulmonary circulation in PAH as a result of a reduced 
cardiac output, there is an increased risk of in situ thrombosis rather than 
embolic events.  We will fully inform the subject that there is a probable low 
risk of any embolic event while off warfarin. It is commonplace for us to stop 
warfarin in this patient group for right heart catheterization and we have not 
had any patients suffer adverse effects as a consequence. 
PH secondary to left ventricular failure 
Some patients in the group with left heart disease causing pulmonary 
hypertension may also be on warfarin. This may be because of their pulmonary 
hypertension with similar indications for anticoagulation as explained above 
although anticoagulation is not even mentioned in guidelines for the 
management of this disease13,16,74. 
They may also have atrial fibrillation as a co-morbidity and be on warfarin for 
this. Dunn and Turpie carried out a systematic review on patients receiving long-
term anticoagulant therapy who stopped it for invasive procedures75. 29 
thromboembolic events occurred among 1868 patients (1.6%), including 7 strokes 
(0.4%)  
We will calculate the risk of stroke in each possible study subject with atrial 
fibrillation using the CHADS2 score. We will explain the risk to each individual 
patient – annual risk will vary from 1.9 to 18% depending on their score. The 
patients will only be off warfarin for a matter of days so their actual risk will be 
minimal. 
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3. ‘A full explanation must also be given that patients who are taken off 
warfarin for a period of time will require to be re-loaded with warfarin, 
which can take a number of days for them to come up to full anti-
coagulation’: 
This has been put in the PIS. 
4. ‘For patients coming off warfarin, a letter should be sent to their GP, 
explaining why and for how long’: 
Changes have been made to the GP information sheet to include this. 
5. ‘An explanation should also be given in the PIS of what will happen 
should the date for their right heart catheterisation is changed or 
cancelled, so that patients are not left off warfarin indefinitely’. 
The PIS has been changed to explain to patients that on the rare occasion that 
their right heart catheterisation is delayed or cancelled, they should restart 
their warfarin and that they will be contacted by a member of the study team 
who will advise them on how to do so. 
2.1.11 Blood assays 
Blood samples (10ml) were collected before and at the end of each drug infusion 
into ethylene diamine tetraacetic acid (EDTA) and gel and clot activator tubes. 
The samples were kept chilled until transported to the laboratory where they 
were centrifuged to obtain plasma and serum and stored at -80°C.  
The samples from a selected group of patients were then sent to colleagues at 
Bristol Myers Squibb, Princeton, USA (Joelle Onorato and Carrie Xu) who then 
measured apelin concentrations and passed on the results. This is their method 
of analysis: 
(Pyr1)apelin-13 plasma concentration was determined using immunoprecipitation 
followed by liquid chromatography/mass spectrometry/mass spectrometry 
(LC/MS/MS) analysis.  Briefly, human plasma (500 µL, kept on ice) was first 
treated with 2 x 0.75 mL cold 0.1% formic acid (FA) in isopropanol. Following 
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centrifugation, the supernatants were dried under nitrogen then reconstituted in 
phosphate buffered saline (PBS)/Tween.  For immunoprecipitation, an anti-
(pyr1)apelin-13 monoclonal antibody (Bristol Myers Squibb, Princeton, USA) was 
bound to high capacity Protein G magnetic beads (Promega).  The reconstituted 
human plasma was incubated overnight at room temperature with 25 µL of the 
antibody-bead slurry.  After multiple washes (pyr1)apelin-13 was eluted from the 
bead complex using 0.1% bovine serum albumin (BSA)/0.1% FA in 90:10 
water:methanol. The eluates were analyzed by LC/MS/MS on a Sciex API6500 
mass spectrometer coupled to a Shimadzu Nexera X2 LC-30AD pump and Sil-30AC 
MP autosampler.  Gradient elution was performed on a Waters BEH300 2.1 x 50 
mm column using a mobile phase of 0.1% FA and 0.1% FA in acetonitrile.  The 
transitions monitored were m/z 384.2→424.8 for (pyr1)apelin-13 and m/z 
387.4→426. 8 for the internal standard (13C,15N-(pyr1)apelin-13 from Innovagen).  
For normalization, internal standard was added to all human plasma and 
calibration curve samples prior to starting the sample extraction protocol.  
Calibration curves were generated by spiking (pyr1)apelin-13 standard into blank 
human plasma (purchased from Bioreclamation and heated at 37oC overnight to 
remove any endogenous apelin) and extracting apelin following the identical 
sample extraction protocol described above.  The concentration of (pyr1)apelin-
13 in clinical human plasma was calculated based on the calibration curves, 
using the peak area ratio of measured apelin to internal standard.  The limit of 
quantification of the assay was approximately 4 pM. 
2.1.12 Data and statistical analysis 
The primary end-point of the study is the change in PVR from baseline. This is a 
standard and well validated primary or secondary end-point in clinical trials for 
PAH therapies. Secondary outcomes included change in CO and systemic vascular 
resistance (SVR). Based on previous studies76-81 investigating the acute 
pulmonary haemodynamic effects of PAH treatments, we calculated that to see 
an effect size of 20% (standard deviation of 149 dyn.s.cm-5), we would need a 
sample size of around 2181 at 80% power and two-sided P<0.05.  
Parameters are reported as mean ± SEM and analysed with repeated-measures 
ANOVA with posthoc Bonferroni corrections  (Graph-Pad Prism, GraphPad 
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Software Inc, San Diego, California). Statistical significance was taken two-sided 
p<0.05.  
2.1.13 Funding 
In order to fund the study I applied for funding from the British Heart 
Foundation, which included funding for myself to run the pulmonary arterial 
hypertension arm of the study, as well as for a salary to recruit a clinical fellow 
at the University of Edinburgh Centre for Cardiovascular Science site, which was 
planned to recruit patients with Pulmonary Hypertension secondary to left heart 
disease and the normal controls. It also allowed funding to purchase an 
ergometer (Figure 2-5, Lode Corvial Supine Ergometer with cardiac stress table) 
for the Edinburgh site and the National Service for Pulmonary Hypertension at 
Hammersmith Hospital in London. The Scottish Pulmonary Vascular Unit in 
Glasgow already had this ergometer. The funding also paid for consumables for 
the right heart catheter studies including staffing required for the studies, for 
(Pyr1)-Apelin-13 (Clinalfa AG, Laufelfingen, Switzerland), and for the pharmacy 
costs in storing this which included purchase of a freezer. 
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2.2 Basic Science Study – in vitro 
2.2.1 Materials 
All general chemicals were of analar grade. 
Tissue plastic-ware were obtained from Greiner Labortechnik Ltd 
(Gloucestershire,UK), Costar (Uk) and Corning Incorporated (NY,USA). 
Solution/chemical Composition/Source 
10% and 20% Culture 
medium 
500ml Dulbecco’s Modified Eagles Medium (DMEM) 
(Sigma,UK) 
50mls (10%) or 100mls (20%) fetal calf serum (FCS) 
800iu penicillin-streptomycin (Sigma,UK) 
8mM L-glutamine (Invitogen,UK) 
 
Serum free medium 500ml Dulbecco’s Modified Eagles Medium (DMEM) 
(Sigma,UK) 
800iu penicillin-streptomycin (Sigma,UK) 
8mM L-glutamine (Invitogen,UK) 
 
Phosphate buffered 
saline (PBS) solution 
2x Phosphate buffered saline tablets (Sigma, UK) 
400mls distilled water 
composition: 0.01 M phosphate buffer, 0.0027 M 
potassium chloride and 0.137 M sodium chloride, 
pH 7.4. 
Trypsin solution 100mls 0.5% Trypsin-EDTA 10x (Fisher Scientific, 
UK) 
400mls PBS solution 
cryopreservation 
medium 
1ml dimethyl sulphoxide (Sigma, UK) 
9mls 10% culture medium 
5% Trichloroacetic acid 4.1g powdered trichloroacetic acid 
500mls distilled water 
0.3M sodium hydroxide 
solution 
6g sodium hydroxide pellets (Sigma, UK) 
500mls distilled water 
Radioimmunprecipitaion 
assay (RIPA) buffer 
Thermo Fisher Scienticfic 
methyl-3[H] Thymidine Amersham (UK) 
Trypan blue stain Gibco (UK) 
Ethanol  
Ecoxcint XR Scintillation 
fluid 
National Diagnostic 
SDS sample buffer Bioland scientific 
10% non-fat milk in PBS 200ml distilled water 
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1x Phosphate buffered saline tablets (Sigma, UK) 
20 gram milk powder (Marvel) 
Wash buffer (0.2% PBS 
Tween wash) 
10x Phosphate buffered saline tablets (Sigma, UK) 
2 litres distilled water 
4 mls Tween detergent (Thermo Fisher Scientific) 
5% non-fat milk in wash 
buffer 
200mls wash buffer (as above) 
10 grams milk powder (marvel) 
Enhanced 
Chemoluminescence 
(ECL) solution. 
Reagents 1 & 2 
Thermo Fisher Scientific 
Apelin (experimental) genscript 
APJ receptor antibody MBL Int Corp. 
Total p38 MAP kinase 
antibody 
cell signaling 
phosphorylated p38 
MAP kinase antibody 
cell signalling 
Table 2-1 Details of commonly used experimental solutions 
 
Galaxy R incubators were supplied by Wolf Laboratories (Figure 2-12, York, UK). 
To minimise chances of fungal and bacterial contamination all procedures 
involving making up of solutions or changing media were performed in sterile 
conditions using a clean Microflow laminar flow hood (Figure 2-10, Model number 
M25121/1). Non-sterile equipment was sterilised using a Prestige Medical ‘classic 
210’ autoclave. Solutions were warmed to 37°C in a waterbath before using with 
cell cultures. 
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Figure 2-10 Microflow laminar flow hood 
 
2.2.2 Animal models 
2.2.2.1 Rat model 
Rat pulmonary arteries were supplied by my colleague Dr Colin Church. Sprague-
Dawley rats were used and all animals were kept in pathogen-free conditions in 
facilities managed by the biological services staff at the University of 
Strathclyde, under strict accordance with the guidelines laid out in the United 
Kingdom Home Office Animals (Scientific procedures) Act 1986. Dr Church 
supplied pulmonary arteries from normal healthy rats, as well as two rat models 
of pulmonary hypertension; a chronic hypoxic model and a monocrotaline model. 
Both are classic models of pulmonary hypertension and well established in the 
literature82. 
The chronic hypoxic model was developed by placing rats in a hypobaric hypoxic 
chamber for a period of 14 days. The monocrotaline model was developed by 
injecting rats subcutaneously with 60mg/kg of monocrotaline. The 
monocrotaline animals developed signs of pulmonary hypertension over 2-3 
weeks. Both animal models showed evidence of pulmonary hypertension both 
haemodynamically (right ventricular systolic pressure was measured under 
anaesthesia) and histologically. 
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2.2.3 Primary cell culture 
The principal cells utilised for the experiments in this thesis were pulmonary 
artery fibroblasts (Figure 2-11). These were derived from rat or cow. The 
explant technique is well established in the Scottish Pulmonary Vascular Unit 
laboratory and has been previously published83. 
 
Figure 2-11 Typical appearance of rat pulmonary artery fibroblasts 
 
The main pulmonary artery was dissected from the lung. This was cleaned of 
adipose tissue then cut longitudinally and opened into a flat sheet. Muscular 
tissue and endothelial cell layers were removed by gentle abrasion of the vessel 
using a sterile razor blade to leave the adventitia. The remaining tissue was 
dissected into 5mm2 pieces. These were evenly distributed in a 25cm3 tissue 
flask containing 1.5mls of 20% culture medium. The flasks were placed in a 
humidified atmosphere in the laboratory’s incubator with 5% CO2 and 21% O2 at a 
controlled temperature of 37°C. Within a few days cells were observed growing 
out from the explants. When required a further 0.5mls of 20% culture medium 
was added to the flask. Once 50% of the flask was covered in a monolayer of 
cells they were detached from the flask by trypsinisation (as described in 
chapter 2.2.4.1) in order to transfer them to a fresh 75cm3 culture flask to allow 
expansion of the number of fibroblasts. The explants were removed before 
transfer to the 75cm3 culture flask. 
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Cells had the typical appearance and morphology of fibroblasts, were negative 
for smooth muscle α−actin and positive for vimentin at western blot. 
2.2.4 Cell maintenance 
Cells were routinely grown in 75cm3 culture flasks with 10% culture medium.  
The cells were kept in the laboratory’s incubator with 5% CO2 and 21% O2 at 
humidified 37°C. The culture medium was changed every 2-3 days and the cells 
were passaged just prior to being fully confluent in the flask. 
2.2.4.1 Cell passage 
Cells were used in experiments between passages 2 and 6. To passage the cells 
the culture medium was removed and they were washed with serum free 
medium. This was removed and the cells were then washed with 2mls of trypsin 
solution. This was left for 10 seconds then the excess was removed. The flask 
was then placed back in the incubator at 37°C for 2-5 minutes until the cells had 
detached from the flask surface (inspected by light microscopy). The flask was 
gently agitated to aid cell detachment. The trypsin was then deactivated by 
adding 10mls of 10% culture medium to create a cell suspension. 1-2mls of the 
cell suspension was added to a new 75cm3 culture flask and topped up to 10mls 
with fresh 10% culture medium. The remaining cell suspension was further 
diluted with 10% culture medium and aliquoted into 6, 12 or 24 well plates for 
experimentation. 
2.2.4.2 Cell storage 
Confluent cells at an early passage were trypsinised with the same protocol as 
for cell passage and resuspended in 10mls of 10% culture medium. The 
suspension was then centrifuged at 3000rpm for 10 minutes at room 
temperature. The culture medium was carefully removed leaving a cell pellet at 
the bottom of the centrifuge tube. This cell pellet was resuspended in 1 ml of 
cryopreservation medium which was transferred to a 2ml cryotube and cooled 
for 1 hour each at +4°C, -20°C then at -80°C overnight before transfer into liquid 
nitrogen chamber (-200°C). 
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When required, frozen cells were removed from the liquid nitrogen chamber and 
thawed in a water bath at 37°C. The cell suspension was then transferred into a 
75cm3 culture flask containing 9mls 10% culture medium. Once the cells had 
adhered to the flask the culture medium was changed. 
2.2.5 Acute hypoxia 
The Galaxy R incubator (Figure 2-12) allowed control of oxygen levels between 
0-21% due to nitrogen supplementation as well as providing a humidified, 
temperature-controlled atmosphere with CO2 levels being maintained at 5%.  
 
Figure 2-12 Galaxy R incubator 
 
The lab contained 2 Galaxy R incubators, one which was maintained at normoxic 
experimental conditions, whilst the other was maintained at 5% O2 to provide 
hypoxic experimental conditions for the cells. The laboratory has previously 
established that cells maintained in this environment for 48hours achieves a PO2 
of 35mmHg and a stable physiological pH. 
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2.2.6 Determination of cell viability and proliferation 
2.2.6.1 Cell counting and viability 
Cells were seeded into plates and appropriate experiments were performed. At 
completion of the experiment the cells were trypsinised with 400μl of trypsin 
solution. The detached cells were then resuspended in 1ml of PBS. 10μl of the 
mixture was then mixed with 10μl of 0.4% trypan blue stain. 10μl of the resultant 
mixture is transferred to a Neubauer Haemocytometer. non-viable cells are 
permeable and take up the blue stain. The haemocytometer is placed under a light 
microscope at x10 power and the grids etched onto the haemocytometer allow 
counting of the viable and non-viable cells. 
The equation for total number of cells in the original solution is shown as Equation 
2-4: 
𝑁𝑁𝐶𝐶𝐶𝐶𝑁𝑁𝑂𝑂𝑁𝑁 𝐶𝐶𝑜𝑜 𝑐𝑐𝑂𝑂𝑐𝑐𝑐𝑐𝐶𝐶 𝐶𝐶𝑂𝑂 𝐶𝐶𝑁𝑁𝐶𝐶𝑂𝑂𝐶𝐶𝑂𝑂𝑜𝑜𝑐𝑐 𝐶𝐶𝐶𝐶𝑐𝑐𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝑂𝑂 =  2 ×  𝑇𝑇𝐶𝐶𝐶𝐶𝑜𝑜𝑐𝑐 𝑂𝑂𝐶𝐶𝐶𝐶𝑁𝑁𝑂𝑂𝑁𝑁 𝐶𝐶𝑜𝑜 𝑐𝑐𝑂𝑂𝑐𝑐𝑐𝑐𝐶𝐶 𝑐𝑐𝐶𝐶𝐶𝐶𝑂𝑂𝐶𝐶𝑂𝑂𝑐𝑐 𝐶𝐶𝑂𝑂 4 𝐶𝐶𝑠𝑠𝐶𝐶𝑜𝑜𝑁𝑁𝑂𝑂𝐶𝐶4  ×  10000 
Equation 2-4 
 
2.2.6.2  [3H] Thymidine proliferation assay 
[3H] thymidine is a radioactive labelled thymidine. Under different experimental 
conditions [3H] thymidine is incubated with cells. During each cell division the 
cells will incorporate [3H] thymidine into its DNA. The more cell divisions (ie the 
higher the proliferation rate) the more radioactivity will be incorporated into 
the DNA. This can then be measured. 
Cells were seeded into 24 well plates at a density of 5x103 - 1x104 cells/well with 
500μl of 10% culture medium. The plates are returned to the incubator until they 
reach 60% confluency. The cells were then quiesced (growth arrested) by 
replacing the medium with serum-free medium and placed in the incubator for 
24 hours. The cells were then ready for their experimental conditions. They 
were then stimulated with appropriate agonists and incubated in the normoxic 
incubator or in the hypoxic incubator where the O2 was reduced to 5% for 24 
hours. 
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Dilute [3H] thymidine was prepared by adding 10μl of stock solution (1 mCi/ml) to 
2.5mls of serum-free medium. At 20 hours 25μl of the dilute [3H] thymidine 
solution is added to each well to allow incorporation of the radiolabeled thymidine 
into the cells DNA during the final 4 hours of the experiment. 
To end the experiment the reaction was stopped by washing the cells twice with 
ice-cold PBS solution. The wells were then washed three times with 
trichloroacetic acid which precipitates nucleic acid polymers longer than ~20 
nucleotides and therefore separates radiolabeled nucleotides incorporated into 
nucleic acid from unincorporated label. The lipid fractions were then solubilised 
by washing twice with 100% ethanol. The final precipitants were then dissolved 
in 0.3M sodium hydroxide solution and left for 30 minutes. 500μl of each solution 
was added to each well per wash. 
The resultant solution was aspirated from each well and added to a 1ml eppendorf 
tube. 0.9mls of Ecoscint XR scintillation fluid. The vials were agitated then left to 
settle overnight. The resultant radioactivity was measured by a scintillation counter 
and expressed as either counts per minute (CPM) or disintigrations per minute 
(DPM). 
2.2.7 Detection and analysis of proteins 
2.2.7.1 Preparation of samples for protein analysis 
Cells were grown on 6 well plates and grown to 90% confluency with 10% culture 
medium. They were then quiesced with serum-free medium for 24 hours before 
being stimulated by agonist and placed in either normoxic or hypoxic incubators 
for 24 to 48 hours. 
The culture plates were removed from the incubators and placed on ice. The 
culture medium was removed and the cell monolayer was washed twice with 
500μl of ice-cold PBS. The cells were then lysed and the proteins solubilised with 
50μl of radioimmunoprecipitation assay (RIPA) buffer for 10 minutes. The cells 
were then mechanically disrupted by using a cell scraper and the contents of each 
well were transferred to 1ml eppendorf tubes sitting in ice then stored at -80°C. 
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2.2.7.2 Western blot procedure: Gel electrophoresis 
The samples for protein analysis were prepared by adding SDS-sample buffer and 
reducing agent at an appropriate concentration. The proteins were then 
denatured by heating to 70°C for 10 minutes. 20 μL of sample was loaded into 
Sodium Dodecyl Sulphate Polyacrylamide (SDS-PAGE) 10% gels (Invitrogen) along 
with a molecular marker in a separate well (See-blue Plus 2, Invitrogen) which 
allowed determination of the protein sizes. 
The gels were loaded into a Novex Xcell mini-cell electrophoresis unit (Figure 
2-13) with running buffer (Invitrogen). 150V were applied for 1 hour or until the 
proteins reached the bottom of the gel. 
 
Figure 2-13 Novex Xcell mini-cell electrophoresis unit with gel loaded 
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2.2.7.3 Western blot procedure: Transfer to nitrocellulose membrane 
The gels were carefully removed from their cassettes and transferred to a 
nitrocellulose membrane using Novex Xcell blot module and transfer buffer 
(Invitrogen). 30V was applied for 1 hour.  
2.2.7.4 Western blot procedure: immunoblotting 
The nitrocellulose membrane is then blocked with 10% non-fat milk (Marvel) in 
phosphate buffered saline (PBS) by agitating at room temperature on a Gyro 
Rocker (Stuart Scientific) then incubating at 4°C overnight.  
The membranes were then placed in a solution of 5% non-fat milk in wash buffer 
with primary antibody at a dilution of 1:500 to 1:1000. The membranes were 
agitated at room temperature for 2 hours in primary antibody before being 
washed with 2 litres of washer buffer.  
The membrane was then incubated for a further 1 hour in 5% non-fat milk in 
wash buffer with 1:1500 dilution of secondary antibody conjugated to 
horseradish peroxidase (HRP). 
To detect the protein bands the membranes were then incubated in Enhance 
Chemiluminescence (ECL) solution (Amersham) for 1 minute and placed in a 
developing cassette with a xray film for different periods of exposure. The film 
was developed using a Kodak X-OMAT processor. 
2.2.7.5 Western blot procedure: densiometry 
Using Image J software (a Java based freeware by Wayne Rasband from National 
Institute of Health, USA) the protein bands were relatively quantified from the 
western blot films. The quantification reflects the relative amounts as a ratio of 
each protein band relative to the lane’s loading control.  
2.2.8 Cell migration 
The migratory capacity of pulmonary artery fibroblasts was investigated with the 
use of Cytoselect 24-well cell migration assay kit (Cell biolabs, Inc.).  
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A fibroblast cell suspension of 0.5-1.0 x 106 cells/ml in serum free media. 300 μL 
of this solution was added to each insert which had a porous membrane as its 
base. The membrane acts as a barrier to discriminate migratory cells from non-
migratory cells. The inserts are placed in a lower chamber containing media 
and/or chemoattractant(s) and incubated in a cell incubator at 37°C for 24 hours 
(Figure 2-14 A). Migratory cells will pass through the porous membrane (Figure 
2-14 B). The inserts were then washed to remove all non-migratory cells (Figure 
2-14 C). The insert is then stained using Cell Stain Solution for 10 minutes at 
room temperature (Figure 2-14 D). 
 
Figure 2-14 Cytoselect Migration assay 
 
The cells on the bottom of the membrane could then be counted directly using 
light microscopy.  
2.2.9 Data and statistical analysis 
For normally distributed values, responses were reported as mean +/- SEM. 
Student t-test was used. For multiple comparisons of means across different 
experimental groups analysis of variance (ANOVA) was performed with 
Bonferonni post hoc analysis. (Graph-Pad Prism, GraphPad Software Inc, San 
Diego, California). Statistical significance was taken two-sided p<0.05. 
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3 Results: Clinical study 
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3.1 Pulmonary Arterial Hypertension Group 
For the pulmonary arterial hypertension group I managed to recruit 20 subjects. 
As explained in the methods & materials chapter, because PAH is a rare disease, 
to make recruitment of our sample size of 21 realistic and feasible we 
collaborated with The National Pulmonary Hypertension Service at Hammersmith 
Hospital in London.  
The Glasgow site recruited 15 subjects for the PAH group.  Subject 301 (the first 
recruited) was excluded from analysis as this study was carried out with the 
original apelin doses of 30, 100 and 300 nmol/min before the amendment to 
change the doses to 10, 30 and 100 nmol/min. The London site recruited 6 
subjects for the PAH group. Unfortunately for one of the studies in London, 
there was a miscommunication between members of the study team meaning 
only half of the study protocol was carried out before the study was abandoned. 
The subject only received infusion A but did not enter the crossover part of the 
study and so did not receive infusion B. This was reported to the National 
Research Ethics Service in the annual report as a breach of protocol and the 
study was excluded from analysis.  
The total number of study recruits included in analysis for the PAH arm of the 
study was 19. 
3.1.1 Baseline demographics 
This study had a crossover design meaning that each subject served as his or her 
own control. Table 3-1 shows the baseline demographics of the subjects 
recruited. 
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Table 3-1 Demographic and haemodynamic characteristics at baseline 
 
3.1.2 Results from resting studies 
In comparison to saline placebo, (Pyr1)apelin-13 infusion reduced PVR (p=0.001) 
with an effect that appeared maximal at 30 nmol/min (Figure 3-1). (Pyr1)apelin-
13 infusion increased CO (p<0.0001) and stroke volume (SV) (p<0.0001) but did 
not affect heart rate or mean pulmonary artery pressure (mPAP) Pulmonary 
artery wedge pressure was also not affected by (Pyr1)apelin-13 infusion (data not 
shown). Consistent with Professor Newby’s previous systemic studies58,59, 
(Pyr1)apelin-13 caused a reduction in systemic vascular resistance (SVR) 
(p<0.05).  
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Figure 3-1 Percentage change in baseline haemodynamics during resting infusions 
Percentage change from baseline in pulmonary vascular resistance, cardiac output, heart rate, 
mean pulmonary artery pressure, stroke volume, mean arterial pressure and systemic vascular 
resistance during infusion of (Pyr1)apelin-13 (☐) or matched saline placebo () in patients with 
pulmonary arterial hypertension. *p<0.05,  **p=0.01, ***p=0.001, ****p=0.0001 2-way ANOVA with 
posthoc bonferroni tests. 
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3.1.3 Results from exercise studies 
No difference was seen in any of the haemodynamic variables during exercise 
except PVR (Figure 3-2) which fell during (Pyr1)apelin-13 infusion (p<0.05).  This 
was associated with an increase in heart rate (Figure 3-2, p<0.01). 
 
 
Figure 3-2 Percentage change in haemodynamics during exercise 
Percentage change from baseline in pulmonary vascular resistance, cardiac output, heart rate, 
mean pulmonary artery pressure and stroke volume during infusion of (Pyr1)apelin-13 (☐) or 
matched saline placebo () in patients with pulmonary arterial hypertension while undergoing 
exercise protocol. *p<0.05, **p<0.01  2-way ANOVA with posthoc bonferroni tests. 
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3.1.4 Post-hoc analysis: Results analysed by age group 
3.1.4.1  Haemodynamics in PAH patients  ≤ median age 
  
 
Figure 3-3 Haemodynamics in PAH patients ≤ median age  
Percentage change in pulmonary vascular resistance, cardiac output, heart rate, mean pulmonary 
artery pressure, stroke volume, mean arterial pressure and systemic vascular resistance during 
infusion of (Pyr1)apelin-13 (☐) or matched saline placebo () in patients with pulmonary arterial 
hypertension ≤ median age of 49 years old. *p<0.01,  **p<0.001, ***p<0.0001, 2-way ANOVA with 
posthoc bonferroni tests. 
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3.1.4.2 Haemodynamics in PAH patients  > median age 
 
Figure 3-4 Haemodynamics in PAH patients > median age 
Percentage change from baseline in pulmonary vascular resistance, cardiac output, heart rate, 
mean pulmonary artery pressure, stroke volume, mean arterial pressure and systemic vascular 
resistance during infusion of (Pyr1)apelin-13 (☐) or matched saline placebo () in patients with 
pulmonary arterial hypertension > median age of 49 years old. 
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3.1.4.3 Results: Analysed by age group 
The median age of the subjects is 49 years old and the mean age 52. (The age 
range was 29-73). I did post-hoc analysis on the data to see if there was any 
suggestion that age influenced the results. Subjects who were 49 years old or 
younger had a significant reduction in pulmonary vascular resistance compared 
with the older age group with (Pyr1)apelin-13 infusion (Figure 3-3, p<0.0001). 
This was again with an increase in CO (p<0.0001) and SV (p<0.0001) but with no 
affect on heart rate or mean pulmonary artery pressure (mPAP). (Pyr1)apelin-13 
caused a much more significant reduction in SVR in the younger subjects 
(p<0.001). Patients were asymptomatic but were lying supine on the cardiac 
catheterisation table.  
On reviewing Table 3-1, the main differences between the younger group when 
compared with the older group, is that the younger patients were more likely to 
be female and more likely to be established on treatment prior to undergoing 
the study, in particular they were more likely to be on phosphodiesterase-5 
(PDE5) inhibitors. 
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3.1.5 Post-Hoc Analysis: Results analysed by gender 
3.1.5.1  Haemodynamics in females with PAH 
 
Figure 3-5 Haemodynamics in females with PAH 
Percentage change from baseline in pulmonary vascular resistance, cardiac output, heart rate, 
mean pulmonary artery pressure, stroke volume, mean arterial pressure and systemic vascular 
resistance during infusion of  (Pyr1)apelin-13 (☐) or matched saline placebo () in female patients 
with pulmonary arterial hypertension. *p<0.05,  **p<0.01, ***p<0.001, ****p<0.0001 2-way ANOVA 
with posthoc bonferroni tests. 
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3.1.5.2 Haemodynamics in males with PAH 
 
Figure 3-6 Haemodynamics in males with PAH 
Percentage change from baseline in pulmonary vascular resistance, cardiac output, heart rate, 
mean pulmonary artery pressure, stroke volume, mean arterial pressure and systemic vascular 
resistance during infusion of  (Pyr1)apelin-13 (☐) or matched saline placebo () in male patients 
with pulmonary arterial hypertension. *p<0.05, **p<0.01, 2-way ANOVA with posthoc bonferroni 
tests. 
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3.1.5.3 Results: Analysed by gender 
As the younger age group were more likely to be female (70% of the group), I 
analysed all the results by gender to see if this may be a significant finding. 
Table 3-1 shows that there were 12 females included in the study and only 7 
males. In comparison to saline placebo, (Pyr1)apelin-13 infusion reduced PVR in 
females (Figure 3-5, p<0.001) but not males. In females (Pyr1)apelin-13 infusion 
increased CO (p<0.0001) and SV (p<0.001) and did not affect heart rate (HR) or 
mPAP. In males there was a significant increase in SV but no significant change 
in CO or PVR. There was a trend towards a reduction in HR, seen in the male 
group, which was not significant, but this may have had an effect on the CO and 
PVR not reaching significance. It is difficult to interpret these results as there 
were so few males included in analysis and I suspect if there were higher 
numbers we would find no difference between the gender groups.  
There was no significant change in systemic vascular resistance for either group. 
The only other clinical difference between the two gender groups is that the 
males were more likely to be treatment naïve, although a similar percentage of 
males and females were treated with phosphodiesterase-5 inhibitors (Table 3-1). 
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3.1.6 Post-Hoc Analysis: Results analysed by subjects pre-study 
treatment 
3.1.6.1 Haemodynamics in patients treated with PDE5 inhibitors 
 
Figure 3-7 Haemodynamics in patients treated with PDE5 inhibitors 
Percentage change from baseline in pulmonary vascular resistance, cardiac output, heart rate, 
mean pulmonary artery pressure, stroke volume, mean arterial pressure and systemic vascular 
resistance during infusion of  (Pyr1)apelin-13 (☐) or matched saline placebo () in patients with 
pulmonary arterial hypertension who are on treatment with phosphodiesterase-5 inhibitors. 
*p<0.05, ** p<0.01, ***p<0.001, **** p<0.0001 2-way ANOVA with posthoc bonferroni tests. 
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3.1.6.2 Haemodynamics in patients not treated with PDE5 inhibitors 
 
Figure 3-8 Pulmonary Vascular Resistance in patients not treated with PDE5 inhibitors 
Percentage change from baseline in pulmonary vascular resistance, cardiac output, heart rate, 
mean pulmonary artery pressure, stroke volume, mean arterial pressure and systemic vascular 
resistance during infusion of  (Pyr1)apelin-13 (☐) or matched saline placebo () in patients with 
pulmonary arterial hypertension who are not on treatment with phosphodiesterase-5 inhibitors. 
*p<0.05, 2-way ANOVA with posthoc bonferroni tests. 
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3.1.6.3 Haemodynamics in patients on any treatment 
 
Figure 3-9 Haemodynamics in patients on any treatment 
Percentage change from baseline in pulmonary vascular resistance, cardiac output, heart rate, 
mean pulmonary artery pressure, stroke volume, mean arterial pressure and systemic vascular 
resistance during infusion of  (Pyr1)apelin-13 (☐) or matched saline placebo () in patients with 
pulmonary arterial hypertension who are established on any treatment. *p<0.05, **p<0.01, *** 
p<0.001, ****p<0.0001, 2-way ANOVA with posthoc bonferroni test. 
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3.1.6.4 Haemodynamics in treatment naïve patients 
 
Figure 3-10 Haemodynamics in treatment naïve patients 
Percentage change from baseline in pulmonary vascular resistance, cardiac output, heart rate, 
mean pulmonary artery pressure, stroke volume, mean arterial pressure and systemic vascular 
resistance during infusion of  (Pyr1)apelin-13 (☐) or matched saline placebo () in patients with 
pulmonary arterial hypertension who are treatment naïve. *p<0.05, 2-way ANOVA with posthoc 
bonferroni tests. 
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3.1.6.5 Results: Analysed by pre-study treatment 
In comparison to saline placebo, (Pyr1)apelin-13 infusion reduced PVR (Figure 
3-9, p<0.0001) in subjects who were on treatment but not on those who were 
treatment naïve (Figure 3-10). When analysed further this effect seemed to be 
due to phosphodiesterase-5 inhibitors. As in the previous analysis this reduction 
in PVR was seen with and increase in CO (p<0.0001), increase in SV (p<0.0001) 
and no change in HR or mPAP. There was also a reduction SVR (p<0.01) (Figure 
3-7).  
11 out of 19 subjects were on phosphodiesterase-5 inhibitors (58%). Only 26% of 
subjects were treatment naïve (Table 3-1). Of the subjects not treated with 
phosphodiesterase-5 inhibitors and those who were treatment naïve, there was a 
significant increase in SV (Figure 3-10, p<0.05). It may be that higher numbers 
would show a significant change in PVR and CO in these groups. 
3.1.7 Results: Blood assay 
In a subset of patients (n=8) we measured serum apelin concentrations pre and 
post infusion of both (Pyr1)apelin-13 infusion and saline placebo. There was no 
detectable basal levels but following infusion with (Pyr1)apelin-13 there was a 
significant increase in apelin levels (Figure 3-11).  
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Figure 3-11 Apelin serum concentrations. 
Serum apelin concentration (pM) before and after infusion of  (Pyr1)apelin-13 or matched saline 
placebo in patients with pulmonary arterial hypertension. *p<0.05, paired T test. 
 
3.1.8 Conclusion 
This study has shown for the first time that acute apelin infusion reduces PVR 
and increase CO and SV in patients with PAH. Due to its acute haemodynamic 
effects and antiremodelling effects the apelin-APJ pathway may be an exciting 
potential therapeutic target for the treatment of pulmonary arterial 
hypertension. Further studies are required to determine the longterm effects of 
APJ agonism in PAH and development of an oral preparation that can easily 
deliver prolonged APJ agonism is needed
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3.2 The remaining 2 groups 
3.2.1 PH due to Left Heart Disease 
The grant procured provided funding for a clinical fellow to be based in 
Edinburgh to recruit for this arm of the study. Dr Colin Stirrat went on to be 
employed in this role, carried out the studies and analysed the data.  
The Scottish Pulmonary Vascular Unit was based in the National Services Division 
at the Golden Jubilee National Hospital which also included the Scottish 
Advanced Heart Failure Service. Patients around Scotland with advanced heart 
failure who are suitable for consideration of cardiac transplant are assessed and 
treated here. This allowed the opportunity to recruit patients in Glasgow to this 
arm of the study.  
I recruited 2 patients from Glasgow to this arm of the study.  
There were some problems encountered during recruitment for this arm of the 
study. As an example the first subjects identified and assessed as possible study 
subjects were: 
1. 12/7/12 – Study cancelled due to patient developing AKI and hypotension 
(systolic blood pressure 60 mmHg) 
2. 14/7/12 – Study postponed due to patient developing pneumonia. Patient 
later recruited as subject 202 on 27/11/12. 
3. 22/8/12 – Patient agreed to participate in study but repeat right heart 
catheterisation (done routinely in transplant candidates) demonstrated 
that previously elevated mean pulmonary artery pressure had improved 
after treatment optimisation and no longer meets study recruitment 
requirements. 
4. 11/9/12 – Study cancelled as subject hypotensive (systolic BP 65 mmHg). 
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5. 19/9/12 – Study 201 carried out. 
6. 26/9/12 – Subject agreed to participate in study but had an ischaemic 
cerebrovascular infarct prior to the study being carried out. 
7. 15/10/12 - Patient agreed to participate in study but repeat right heart 
catheterisation demonstrated that previously elevated mean pulmonary 
artery pressure had improved after treatment optimisation and no longer 
meets study recruitment requirements. 
8. 7/11/12 - Patient agreed to participate in study but repeat right heart 
catheterisation demonstrated that previously elevated mean pulmonary 
artery pressure had improved after treatment optimisation and no longer 
meets study recruitment requirements. 
9. 13/11/15 - Patient agreed to participate in study but repeat right heart 
catheterisation demonstrated that previously elevated mean pulmonary 
artery pressure had improved after treatment optimisation and no longer 
meets study recruitment requirements. 
10. 27/11/15 - Study 202 carried out. 
I think the problems recruiting to this arm of the study at the Glasgow site was 
that the heart failure population tended to be younger and more unwell as they 
were being assessed for transplant. As can be seen, when these patients are 
optimally treated, their right heart pressures tend to improve and it may be the 
subset of patients with pulmonary vascular remodelling and the more severe 
phenotype (See chapter 1.1.2.2) are very rare. 
The other patients recruited for this arm of the study were done so in a more 
conventional group of heart failure patients at the Edinburgh site by Dr Colin 
Stirrat, whom also collated and analysed the data. In total 14 subjects were 
recruited to this group (with 4 of these undergoing the exercise protocol). 
Unfortunately the results did not show any significant difference (Figure 3-11) in 
haemodynamic effects between (Pyr1)apelin-13 infusion and saline placebo in 
this group. He will write up the results for his own thesis. 
86 
 
 
Figure 3-12 Cardiac Output in patients with left heart failure 
Percentage change from baseline in cardiac output during infusion of  (Pyr1)apelin-13 (blue circles) 
or matched saline placebo (Black line) in patients with left heart disease. 
 
3.2.2 Healthy Volunteers 
These subjects were recruited by Dr Colin Stirrat at the Edinburgh recruitment 
site who managed to recruit 7 healthy volunteers. All 7 subjects underwent the 
full study protocol including the exercise component. Unfortunately the results 
did not show any significant difference (Figure 3-12) in haemodynamic effects 
between (Pyr1)apelin-13 infusion and saline placebo in this group. Dr Colin 
Stirrat will write up the results of this group for his own thesis. 
 
Figure 3-13 Cardiac Output in healthy volunteers 
Percentage change from baseline in cardiac output during infusion of  (Pyr1)apelin-13 (blue circles) 
or matched saline placebo (Black line) in healthy volunteers. 
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4 Results: The role of apelin in pulmonary 
vascular remodelling
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4.1 Basic science results 
As a small additional study to the clinical trial, I worked in the SPVU laboratory 
to determine some of the effects apelin has on pulmonary artery fibroblasts. As 
previously discussed, there are extensive structural changes within the 
pulmonary vasculature by remodelling of the 3 layers of the vessel wall (intima, 
media and adventitia) which results in luminal obliteration and increased 
pulmonary vascular resistance. Our lab has a long history of studying the 
importance of the pulmonary artery fibroblast in this process83-85. There is also 
emerging evidence that fibroblasts are critical regulators of vascular wall 
function and release inflammatory mediators which may play an important role 
in the development of pulmonary hypertension86. 
4.1.1 Anti-proliferative effect of apelin on pulmonary artery 
fibroblasts 
As has previously been demonstrated, pulmonary artery fibroblasts proliferate in 
cell culture in response to increasing doses of fetal calf serum. If the pulmonary 
artery fibroblasts are incubated in a hypoxic incubator (5% oxygen) for 24 hours, 
this prompted an increase in proliferation (columns 1 and 2 in Figure 4-1). This is 
data our lab has shown previously87. The lab went on to show that p38 MAP 
kinases are activated by acute hypoxia in pulmonary artery fibroblasts as well as 
in fibroblasts derived from rats exposed to chronic hypoxia. We believe that p38 
MAP kinase activity is an important pathway for the proliferation of pulmonary 
artery fibroblasts and plays an important role in pulmonary artery remodelling84. 
I postulated that apelin may have an antiproliferative effect on pulmonary 
artery fibroblasts. Figure 4-1 demonstrates that apelin inhibited the proliferative 
response to hypoxia in the pulmonary artery fibroblast. 
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Figure 4-1 Apelin inhibits the proliferative response to hypoxia in the pulmonary artery 
fibroblast 
[3H] thymidine proliferation assay of rat pulmonary artery fibroblasts grown in both serum starved 
and 1% FCS conditions +/- apelin. The cells were then incubated in normoxic or hypoxic incubators 
for 24hours. Hypoxia causes increased proliferation of the cells. Incubation with apelin attenuated 
this proliferation. n=2. * p<0.001 ** p<0.05 
 
4.1.2 Cell migration 
In pulmonary hypertension, pulmonary artery fibroblasts migrate from the 
adventitia into the media layer as part of the pulmonary vascular remodelling 
process. Using a Cytoselect migration assay, which allows migration through a 
semi-permeable membrane we showed that pulmonary artery fibroblasts showed 
increased cell motility in response to acute hypoxia (Figure 4-2). When the 
experiment was repeated in the presence of apelin, this increase in cell 
migration was prevented (p<0.005). 
* 
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Figure 4-2 Cell migration of pulmonary artery fibroblasts when exposed to hypoxia is 
reduced by apelin 
Rat pulmonary artery fibroblasts show increased migration when exposed to hypoxia using the 
cytoselect migration assay. This migration was attenuated when the cells were incubated with 
apelin. n=2. * p<0.005 
 
4.1.3 Immunoblotting 
First we looked to see with immunoblotting whether the apelin receptor, APJ 
was present in rat pulmonary artery fibroblast cells (Figure 4-3).  
 
Figure 4-3 APJ receptor presence in rat pulmonary artery 
Western blot analysis of APJ receptor presence in rat pulmonary artery fibroblasts. Rat pulmonary 
artery fibroblasts were cultured in normoxic and hypoxic chambers. (Total p38 MAP kinase as 
control). 
 
91 
 
As our lab has previously shown, proliferation of pulmonary artery fibroblasts in 
hypoxia may be due to activation of the p38 MAP kinase pathway. As apelin 
prevented the hypoxic proliferation of pulmonary artery fibroblasts, I postulated 
that apelin may be inhibiting the activation of this pathway. To examine the 
activity of p38 MAP kinases, I carried out western blot analysis of total p38 MAP 
kinase as a control and the active phosphorylated p38 MAP kinase in response to 
hypoxia with and without incubation with apelin.  
 
Figure 4-4 Increased phosphorylation of p38 AMP kinase to hypoxia was reduced by apelin 
Rat pulmonary artery fibroblasts were cultured +/- FCS, +/- apelin. Hypoxia has previously been 
shown to increase the phosphorylation of p38 MAP kinase. Incubation with apelin reduced this 
effect. 
 
By immunoblotting we showed that active phosphorylated p38 MAP kinase 
increased in response to hypoxia as expected. However, when pulmonary artery 
fibroblasts were exposed to hypoxia in the presence of apelin this increase in 
phosphorylated p38 MAP kinase was reduced (Figure 4-4). When the blot is 
analysed by densitometry (Figure 4-5) this confirms that there is a significant 
reduction in p38 MAP kinase activity (p<0.05). 
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Figure 4-5  Increased phosphorylation of p38 AMP kinase to hypoxia was reduced by apelin 
Densitometry of the protein bands on the western blot film were carried out to show the relative 
difference between phosphorylation of p38 MAP kinase when exposed to hypoxia +/- apelin. Apelin 
significantly reduced the phosphorylation seen in hypoxia. *p<0.05 
 
4.1.4 Conclusion 
We have shown that rat pulmonary adventitial fibroblasts express the apelin 
receptor – APJ. Apelin prevents the hyperproliferative and cell migratory 
response to hypoxia seen in rat pulmonary artery fibroblasts. Apelin prevents the 
phosphorylation of p38 MAP kinase in response to hypoxia and so its actions may 
in part involve activity through this pathway. 
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5 Final Discussion
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For the first time, this study demonstrates that acute intravenous (Pyr1)apelin-13 
infusion causes a fall in pulmonary vascular resistance with an increase in 
cardiac output and stroke volume in patients with pulmonary arterial 
hypertension. The effect of chronic apelin agonism and its potential role in the 
treatment of PAH needs further exploration. 
Pulmonary Vascular resistance is derived from: 
𝑃𝑃𝑃𝑃𝑃𝑃 = 80 × (𝐶𝐶𝑃𝑃𝑚𝑚𝑃𝑃 − 𝑃𝑃𝑚𝑚𝑃𝑃𝑃𝑃)
𝐶𝐶𝑜𝑜𝑁𝑁𝑐𝑐𝐶𝐶𝑜𝑜𝑐𝑐 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶  
mPAP and PAWP did not change with (Pyr1)apelin-13 infusion (Figure 3-1 and 
PAWP not shown). It is therefore the change in cardiac output which leads to the 
improvement in pulmonary vascular resistance.  
Cardiac output itself is calculated from: 
𝐶𝐶𝑜𝑜𝑁𝑁𝑐𝑐𝐶𝐶𝑜𝑜𝑐𝑐 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 = 𝑆𝑆𝐶𝐶𝑁𝑁𝐶𝐶𝑆𝑆𝑂𝑂 𝑃𝑃𝐶𝐶𝑐𝑐𝐶𝐶𝐶𝐶𝑂𝑂 ×  𝐻𝐻𝑂𝑂𝑜𝑜𝑁𝑁𝐶𝐶 𝑃𝑃𝑜𝑜𝐶𝐶𝑂𝑂 
As we saw in Figure 3-1, heart rate was not affected by (Pyr1)apelin-13 infusion 
but stroke volume was.  
Stroke Volume is derived from: 
𝑆𝑆𝐶𝐶𝑁𝑁𝐶𝐶𝑆𝑆𝑂𝑂 𝑃𝑃𝐶𝐶𝑐𝑐𝐶𝐶𝐶𝐶𝑂𝑂 = 𝐸𝐸𝑂𝑂𝑐𝑐 𝐷𝐷𝐶𝐶𝑜𝑜𝐶𝐶𝐶𝐶𝐶𝐶𝑐𝑐𝐶𝐶𝑐𝑐 𝑃𝑃𝐶𝐶𝑐𝑐𝐶𝐶𝐶𝐶𝑂𝑂 –𝐸𝐸𝑂𝑂𝑐𝑐 𝑆𝑆𝑂𝑂𝐶𝐶𝐶𝐶𝐶𝐶𝑐𝑐𝐶𝐶𝑐𝑐 𝑃𝑃𝐶𝐶𝑐𝑐𝐶𝐶𝐶𝐶𝑂𝑂 
The factors which increase stroke volume include;  
1. Increased preload (an increased venous return or fast filling time can 
increase the end diastolic volume and therefore the stroke volume).  
2. Increased contractility (decreases end systolic volume and thereby 
increases stroke volume).  
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3. Reduced afterload (reduced vascular resistance decreases end systolic 
volume and so increases stroke volume). 
 
The current recommendations for treatment goals as set out at the fifth world 
symposium on pulmonary hypertension advise normalization of RV function as a 
treatment goal which is defined as RAP < 8 mmHg and CI >2.5 l/min/m25,88. By 
infusing (Pyr1)apelin-13 into patients with PAH we have managed to improve CO 
as recommended. This suggests that apelin exerts an acute inotropic effect in 
PAH patients. 
Apelin itself may not currently represent a viable therapeutic intervention for 
PAH as its only method of delivery is systemic, however this study has 
demonstrated that activation of the apelin-APJ pathway leads to a significant 
improvement in PVR and CO even in patients established on current PAH 
therapies. Development of drugs which cause APJ agonism need to be developed 
as this would be an exciting approach to treatment of PAH.  
This study was designed as an invasive study as this is the gold standard method 
in measuring pulmonary haemodynamics and the most accurate method for 
determining haemodynamic values. The study design was a within subject 
comparison crossover study in order to gain as accurate results as possible. The 
study was designed to measure both resting and exercise haemodynamics 
because patients with PAH are more symptomatic during activity and I hoped to 
demonstrate that apelin has therapeutic benefit during exercise. Interestingly 
the study demonstrated changes in pulmonary haemodynamics at rest but, 
surprisingly, exercise did not further augment these changes.  This may be 
because of the large changes seen in haemodynamics caused by exercise alone. 
It may be that longer term apelin infusions leads to an improvement in exercise 
pulmonary haemodynamics and this may be worth examining in future studies.  
The apelin system may have major relevance for patients with PAH. Dysfunction 
of BMP signalling is an important pathway in the pathogenesis of PAH61 and it 
appears to markedly influence apelin production as a potential mediator of the 
pathogenesis of PAH. In a chronic hypoxic rodent model of right ventricular 
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failure89, apelin has inotropic effects and treating rats with monocrotaline-
induced pulmonary hypertension with apelin infusion led to improved RV mass 
and haemodynamic variables68. In human studies, apelin expression is reduced in 
the pulmonary artery endothelial cells (PAEC) of patients with idiopathic 
pulmonary arterial hypertension (IPAH)65. Reducing apelin in human PAEC by 
small interfering RNA (siRNA) impairs PAEC survival and promotes pulmonary 
artery smooth muscle cell proliferation65. Furthermore, Apelin can directly 
suppress vascular smooth muscle cell proliferation in response to growth factors, 
and is pro-apoptotic65. Plasma apelin concentrations are reduced in patients 
with IPAH46. 
Professor Newby provided the first evidence that apelin has vasoactive actions in 
humans. He showed that apelin causes vasodilatation in vivo in the human 
forearm circulation of healthy volunteers through a predominantly nitric oxide–
dependent mechanisms, and that this effect is preserved in patients with heart 
failure58,59. Furthermore, apelin is a direct coronary vasodilator and increases 
myocardial contractility in humans. It causes a reduction in both peak and end-
diastolic left ventricular pressures59.  
Included in this study were patients who were taking phosphodiesterase-5 (PDE5) 
inhibitors. It is known that in ex vivo myography studies, inhibition of nitric 
oxide (NO) attenuated vasorelaxation in human mesenteric arteries48. As 
Professor Newby demonstrated58, the effects of apelin are partially attenuated 
with a “NO clamp” (NO synthase inhibitor) suggesting that apelin causes arterial 
vasodilation in a nitric oxide dependent manner. PDE5 inhibitors also act on the 
NO pathway by preventing degradation of cGMP. I felt it was important to 
include this group for recruitment in this study to determine if there was any 
synergistic vasodilatory effect when combining two drugs that act on the NO-
cGMP pathway. I also felt it was important to assess what effect this 
combination of treatment would have on SVR from a safety perspective. 
Interestingly, on post-hoc analysis, the group of patients established on PDE5 
inhibitors had a significant improvement in PVR, CO and SV while the group who 
were not on treatment with PDE5 inhibitors showed no significant effect. This 
study was not powered to investigate this effect but it would be important for 
future studies to explore this effect further. 
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There is a lot of interest currently in upfront combination treatment for PAH and 
whether this has longterm beneficial effects in patients with PAH by the 
establishment of early control and preservation of RV function. This has to be 
weighed up however with the potential for drug to drug interactions and 
potential adverse effects. This study did not demonstrate any adverse effects  
but this would need to be explored further in longterm studies. The group of 
patients on PDE5 inhibitors did have a more significant reduction in SVR. This 
was asymptomatic in this study cohort who were supine on the catheterisation 
table and it may be that this change in SVR may have a more significant effect in 
longer term studies. There was also no significant change in in MAP, possibly 
explaining the lack of symptoms and potentially meaning the reduced SVR would 
have the benefit of improving tissue and organ perfusion via increased blood 
flow to them. 
As reported in the post-hoc analysis data the younger patients had a significant 
improvement in PVR and CO that the older patients didn’t. Again the study was 
not powered to analyse this effect. The demographic data demonstrate that the 
younger age group have a higher RVP, higher mPAP, lower CO, lower SV and 
higher PVR at baseline. The younger age group appear to have 
haemodynamically more severe PAH meaning they may have more to gain from 
the apelin infusion. It is also noted that 90% of the younger group are on PDE5 
inhibitors while only 22% of the older group were on PDE5 inhibitors so the effect 
demonstrated may be reflecting the synergist effect of these two drugs rather 
than a difference between the patients.  This makes it hard to draw conclusions 
about the difference in response between the age groups. 
This study examines the short term effects of apelin administration and longer 
studies would have to be carried out to determine longterm haemodynamic 
benefits as well as longterm adverse effects. Professor Newby has previously 
determined the effect of prolonged systemic infusion of apelin in man. During 6 
hour infusions of apelin in healthy volunteers and patients with heart failure the 
apelin was well tolerated and its inotropic actions were maintained with a 
sustained increase in cardiac index and left ventricular ejection fraction60. 
Furthermore, they monitored pulmonary artery blood flow during the first hour 
of apelin infusion using echocardiography and found this to be increased with 
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apelin infusion versus saline placebo. This suggests that apelin will have 
sustained benefits on pulmonary vascular haemodynamics  
Apelin has also been shown in preclinical studies to target pulmonary vascular 
remodelling65 so not only does it have beneficial haemodynamic effects in the 
human pulmonary vasculature but it may also prevent the pulmonary vasculature 
remodelling seen in PAH. 
It is surprising that the haemodynamic effects apelin exerts in the PAH 
population is not demonstrated in the healthy volunteer group or the group 2 PH 
group. This may be due to the underlying pulmonary vascular changes seen in 
patients with PAH compared to the other 2 groups. The group 2 PH group in 
particular will have to be explored further to clarify if they had ‘reactive’ 
changes in the pulmonary vasculature or whether they have the more severe 
phenotype described in chapter 1 as it would be interesting if possible to do 
subanalysis between these 2 groups and see if the more severe phenotypes had a 
similar response to apelin as the patients with PAH. This would suggest that the 
damaged pulmonary vasculature was in some way being ‘restored’ by the apelin 
and exerting the haemodynamic changes seen. 
(Pyr1)apelin-13  peptide is unlikely to represent a viable long-term therapeutic 
intervention for PAH as it would require continuous intravenous systemic 
infusion. However our study has demonstrated that activation of the apelin-APJ 
pathway led to an important improvement in pulmonary vascular resistance and 
cardiac output even in patients established on current PAH therapies. 
Development of orally active drugs that can cause long-term apelin agonism 
would be an exciting approach to the treatment of PAH.  To make apelin 
agonism a viable potential treatment for patients with PAH, further drug 
development is required to develop an oral or inhaled preparation that can be 
easily delivered to enable prolonged apelin agonism , in order to avoid the 
difficulties of long-term infusion treatments well demonstrated with 
prostacyclin. There are already synthetic agonists of the apelin receptor showing 
some promise in research90.  
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5.1 Limitations 
The main limitations of the clinical study are its short infusion time. A longer 
study will be able to provide more information on longer term effects of apelin 
and in particular may provide more information on potential adverse effects 
such as hypotension. A further limitation of the clinical study is the fact that the 
studies were carried out in the supine position at rest. This was necessary to 
carry out the right heart catheterisation but doesn’t represent real life activity 
for these patients.  
There are limitations in the conclusions that can be drawn from the post hoc 
analysis as the study was not powered to assess these smaller groups. 
5.2 Ideas for further research 
With regards to the clinical study, ideally future research will be around 
developing an oral agonist for the APJ receptor which will have a longer duration 
of action allowing longer term studies of apelin agonism that can provide data 
regarding long term haemodynamic modifications, exercise tolerance changes 
and mortality information. In the meantime, a potential way to examine 
prolonged effects of apelin infusion in patients with PAH would be to carry out a 
similar study to what professor Newby and his colleagues did looking at a 6 hour 
infusion in healthy volunteers and patients with chronic heart failure60. It may 
be less feasible to do this during right heart catheterisation, measuring 
pulmonary haemodynamics, but would be useful in exploring adverse effects 
such as symptomatic hypotension which may be a problem in patients with PAH. 
Newby et al showed that there was a reduction in peripheral vascular resistance 
during the first hour in healthy volunteers but that this was not sustained and 
that mean arterial pressure was unchanged throughout the 6 hour infusion. 
However in patients with chronic heart failure there was a maintained reduction 
in both mean arterial pressure and peripheral vascular resistance throughout the 
6 hour infusion period. 
It would also be interesting to carry out a clinical study looking in particular at 
comparing patients who are and aren’t on treatment with PDE5 inhibitors to see 
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if there is a statistically significant difference in the haemodynamic changes 
seen with apelin in these 2 groups. 
Further laboratory work would be helpful in establishing mechanisms for the 
possible anti-remodelling effects and the mechanistic pathways underlying this. 
Work that may help establish reasons behind the reduced proliferation of rat 
pulmonary artery fibroblasts to hypoxia seen when incubated with apelin would 
include looking at the supernatant from both sides of the study to see if there 
are any particular mediators involved. The mediators released may provide 
insight into which cell signalling pathways may be involved and this may guide 
further laboratory experiments. Similarly looking at the supernatant from the 
migration studies may also provide insight into mechanisms for anti-remodelling. 
Further work could also look at the combination of PDE5 inhibition and apelin to 
see if there is enhancement of the reduced proliferation and migration seen with 
hypoxia. 
Additionally, looking at carrying out these lab experiments in human pulmonary 
artery fibroblasts would be important as there can be significant inter-species 
differences. 
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6 Final Comment
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The work done for this thesis has shown for the first time that acute apelin 
infusion causes a fall in pulmonary vascular resistance in humans with pulmonary 
arterial hypertension. There is also an increase in cardiac output and stroke 
volume.  
As well as the haemodynamic effects of apelin in PAH, we have shown that 
apelin reduces the hypoxic proliferation and migration of rat pulmonary artery 
fibroblasts and that these effects may be exerted through inhibition of the p38 
MAP kinase pathway.  This would suggest that apelin may have an anti-
remodelling role in PAH as well as effects on pulmonary haemodynamics. 
Apelin agonism may represent a future treatment for PAH. The effect of chronic 
apelin agonism and its potential role in treatment of PAH needs further 
exploration. 
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Appendix A   
 
 
 
 
 
Date:  
 
 
 
Dear  
 
STUDY: Haemodynamic Effects of Apelin in Pulmonary Hypertension.  
 
CONTACT:  Dr Lauren Brash 
  Scottish Pulmonary Vascular Unit 
  Golden Jubilee National Hospital 
  Agamemnon Street 
  Clydebank 
  G81 4DY  
 
  Tel: 0141 951 5497 or 07738 569980 
  Email: laurenbrash@nhs.net 
 
We would like to invite you to take part in a research study. Before you decide 
to accept, it is important that you understand why the research is being done 
and what it will involve. Please take time to read the following information 
carefully. Part 1 explains to you about the purpose of the study and what will 
happen to you if you decide to take part. Part 2 gives you more information on 
the conduct of the study. A member 
of the research team will go through 
the information sheet with you and 
answer any questions that you may 
have. You can discuss the 
information with others if you wish. 
This could be friends, family, 
nursing staff, your GP or anyone 
else you would like to talk to. 
 
PART 1 
 
What is the purpose of this study?  
Blood is pumped by the right side of 
the heart to the lungs, where the 
blood cells pick up oxygen from the 
air we breathe. The blood then 
travels back to the left side of the heart which pumps the oxygen enriched blood 
around our body (see figure 1). The oxygen is used by our body’s cells for energy 
and without it we couldn’t survive. 
 
Pulmonary arterial hypertension (PAH) is a rare disease caused by damage to the 
pulmonary arteries (these are the blue blood vessels carrying blood to the lungs 
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in figure 1). This damage causes thickened, narrowed blood vessel walls (see 
figure 2). When a drainpipe in a sink becomes clogged up, the flow of water 
from the sink becomes sluggish and slow. The same happens with the blood flow 
through the narrowed pulmonary arteries. The right ventricle is the muscle on 
the right side of the heart which pumps blood through the pulmonary arteries to 
the lungs. The right ventricle works harder to get the blood flowing through 
these narrowed pulmonary arteries. Initially this increase in work compensates 
for the damage to the pulmonary arteries but over time the right heart is put 
under strain and struggles to pump the blood efficiently. This leads to symptoms 
of breathlessness, fatigue and fluid retention. If untreated these symptoms will 
get worse over time. There are a number of treatments available for PAH, which 
help with the symptoms, but currently no cure. Research is essential to improve 
our knowledge of this condition and help develop new treatments. 
 
There has been research carried out on a protein found in the heart and lungs 
called apelin. This protein has been found to be less active in people who have 
conditions such as PAH and heart failure. There have been studies carried out 
involving the administration of apelin to both healthy volunteers and to patients 
with heart failure. These studies were carried out in Edinburgh by members of 
our research team. These studies showed that apelin increases blood flow in the 
general circulation as well as helping the heart to pump stronger. The effect of 
apelin in the pulmonary circulation is unknown. 
 
The purpose of this study is to assess what effects the study drug, Apelin, has on 
the pulmonary arteries and specifically to see if it helps widen the pulmonary 
artery, thereby improving the flow of blood to the lungs and reducing the strain 
on the right side of the heart. 
 
Why have I been chosen? 
You have been invited to participate because you either have suspected or 
confirmed PAH. We plan to look at the effects of apelin on the pulmonary 
circulation in 3 patient groups; people who have PAH, people who have 
pulmonary hypertension due to heart failure and healthy people with normal 
heart and lungs. It is important to see if apelin has any effects on the pulmonary 
circulation and to see if this effect is lost or maintained in people with PAH or 
heart failure. In total we will ask 63 people to participate in this study from 3 
different sites in the UK. 
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Do I have to take part? 
No. It is entirely your decision about whether to take part or not. If you decide 
to take part, you will be given a copy of this patient information sheet and be 
asked to sign a consent form. If you decide to take part in this study you are free 
to withdraw at anytime without having to give a reason. If you decide not to 
take part or you withdraw at any point in the study the standard of care you will 
receive will not be affected.  
 
What will happen to me if I take part? 
 
You will be asked to give consent: 
If you decide to take part in the study you will first be asked to sign the consent 
form. Be sure that you read all the information you are provided with carefully 
so that you understand what taking part in this study will involve.  
 
You will have a right heart catheterisation procedure: 
On the day of the study you will have a test called a right heart catheterisation. 
PAH causes raised blood pressure in the lung blood vessels. It is possible to 
estimate the pressure using non-invasive methods such as an echocardiogram 
(which uses sound waves to visualise the heart) but this method is much less 
accurate. Right heart catheterisation is considered the only way to definitively 
diagnose PAH. 
 
This procedure involves having an injection of local anaesthetic to numb the skin 
over one of the large veins. This will most likely be one of the large veins in the 
neck but it may be one in the groin. Once the skin is numb, a plastic tube is 
placed in the vein through a small incision. This allows a catheter to be fed 
through to the heart and the lung blood vessels. X-ray pictures are taken to 
check the position of the catheter. Various measurements including pressure can 
be made through special sensors in the catheter. These pressures tell us about 
how high the blood pressure in the lungs is as well as how well the heart is 
pumping. 
 
Everybody with PAH will have a right heart catheterisation to make the 
diagnosis. If you choose to take part in this study we will first carry out the 
routine diagnostic catheterisation. If this confirms that you have PAH, the 
procedure will continue while you receive the study drug. 
 
It may be that you already have a diagnosis of PAH and are already on 
treatment. If this is the case you will have had a right heart catheterisation 
when you were diagnosed. We do not routinely repeat right heart 
catheterisations and although this test will give us more up to date information 
on the severity of your disease, it is unlikely that this will lead to an alteration 
in your management. 
 
You will be given the study treatment: 
You will be given either apelin treatment or placebo treatment in random order 
via a drip while the pressure measurements are repeated. A placebo is a 
‘dummy’ treatment which looks like the active apelin treatment but contains no 
active ingredient. There will then be a half an hour rest period before you are 
given the second treatment. This will be apelin if you received placebo initially 
or placebo if you previously received apelin. Each treatment period will last for 
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15 minutes. This is known as a ‘cross-over’ study, meaning you will receive both 
treatments and your body’s responses will be recorded and compared to see if 
one treatment is better than the other. Both yourself and the doctor taking the 
measurements will not be told which order you receive the treatments. This is 
known as a ‘double-blinded’ study, meaning you are both ‘blinded’ to the 
treatment. It is done to prevent bias when recording the results. The study will 
be unblinded when it is time to analyse the results.  
 
You will have blood tests taken: 
Before the right heart catheterisation is started, you will have a drip placed in 
your arm. This will allow blood samples to be taken during the study period. This 
is to look at apelin levels as well as NT-proBNP, which is a hormone which is 
secreted by the heart in response to excessive stretching of the heart muscles 
(when they are under strain). NT-proBNP is typically elevated in people who 
have either heart failure or PAH.  
 
You will be asked to exercise: 
After the initial measurements are made during the right heart catheterisation, 
you will be asked to carry out some exercise if you are able. This will be in the 
form of cycling while lying flat on the examination couch. You will be asked to 
cycle for a maximum of 5 minutes with no apelin treatment and then for a 
further 5 minutes with apelin treatment.  Each exercise period will be separated 
by a 1 hour rest period in which the other data already discussed is collected. 
Many people with PAH have no symptoms at rest and only have symptoms while 
they are walking or carrying out other activities. It will be useful to look at how 
apelin affects the lung circulation while under the stress of exercise. 
 
How long will the study take?: 
The addition of the study to your diagnostic catheterisation will increase the 
duration of the procedure from around 45 minutes to just over 2 hours. The 
study itself will take place on 1 day.  
 
You will be started on treatment for PAH: 
Once the study is complete, if you are a new diagnosis of PAH, you will be 
started on appropriate therapy. Your specialist team will decide what this should 
be. Current medical treatment for PAH comprises of general strategies such as 
diuretics, digitalis, anticoagulants, and oxygen as well as specialised PAH 
specific medication like Phosphodiesterase Inhibitors (e.g. Sildenafil), Endothelin 
Receptor Antagonists (e.g. Bosentan and Ambrisentan) and Prostacyclin 
Analogues (e.g. Epoprostenol and Iloprost). Your decision regarding participation 
in this study will not affect the choice your team make about which treatment 
to start you on. You can discuss these treatments further with your PAH 
specialist. You will return to clinic for follow up of your PAH but will require no 
further visits for the study. 
 
If you have a known diagnosis of PAH, you should already be established on 
appropriate treatment. It is unlikely that this will be changed. You can discuss 
this further with your specialist doctor. 
 
It is important that you know that this study is being carried out to assess the 
potential effects of apelin on the pulmonary arteries. We do not know for sure 
that it will have any beneficial effect. If it does have a beneficial effect, this 
effect will be short-lived and will not give you any lasting benefit. This is 
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because apelin is broken down and cleared from the body quickly. If this study 
shows that apelin has beneficial effects on the pulmonary arteries, further 
research and trials will need to be carried out before apelin can be developed 
into a practical treatment for PAH. 
 
What if you are on warfarin?: 
You may be on warfarin for your pulmonary hypertension. To be safe to undergo 
the study test you will be asked to stop your warfarin. In general patients with 
pulmonary hypertension are advised to be on warfarin because it is believed that 
those who are treated with warfarin survive longer than those who are not.  
There has been no randomised controlled trial to confirm this belief yet. 
Warfarin can make you more prone to bleeding and patients who have a 
significant contraindication (ie. have bleeding or falls risk) will not be treated 
with warfarin.  
 
The reason for stopping warfarin is that the right heart catheterisation is an 
invasive procedure involving a needle being passed into the large vein in your 
neck. If you remain on warfarin during the procedure, there is an increased risk 
of serious bleeding. There is very little research to suggest that stopping 
warfarin for a short period of time will cause you any problems.  
 
Once the study has been completed you will have to restart the warfarin. It can 
take a few days before the INR reaches the target range of 2 – 3. The study team 
will advise you on what dose to take. Your GP will be notified that you will be 
off warfarin temporarily. On the rare occasion that the study is delayed or 
cancelled, you should restart your warfarin. A member of the study team will 
contact you and advise you on what dose to take. 
 
Please let the study team know if you are on warfarin for any other reason as 
you may not be eligible for the study. If you have any questions, feel free to 
contact the study team using the contact details on the first page. 
 
 
Please feel free to ask your study team any questions regarding any of this 
information. 
 
What does taking part in the study mean to me? 
If you are a new patient, undergoing diagnostic investigations, you will require a 
right heart catheterisation as part of these investigations. If you decide to take 
part in this study, the difference to routine care will be: The duration of the 
right heart catheterisation will be more than twice as long; you will be given an 
experimental treatment; and you will be asked to give additional blood samples. 
The risks are explained in more detail below. 
 
Expenses and Payments 
You will not receive any payment for this study but any expenses you incur such 
as travel will be compensated. You will find out more about this by discussing 
with your research team. 
 
Additional information for women of child bearing potential. 
There is no information on what effect apelin could have on an unborn child, 
therefore, if you are a woman of child bearing potential, you will be asked to 
have a pregnancy test prior to inclusion in the study. Also if you have recently 
109 
 
given birth and are breast feeding your child, you would be excluded from taking 
part in this study. Please inform the study doctor if this is the case. 
 
What are the possible disadvantages and risks of taking part? 
Many of these procedures are necessary for the diagnosis of PAH but have been 
adapted for the purposes of the study. The potential risks are discussed below: 
 
Blood tests: It is likely that you have had blood tests carried out before. The 
main adverse effects can be discomfort, bruising, bleeding and less commonly 
infection. The maximum amount of blood collected will be 120 mls. This is 
around a quarter of what is taken during blood donation. This will be quickly 
replaced by your body. If you have recently donated blood, please inform your 
study doctor. 
 
Right heart catheterisation: Possible complications of this procedure include: 
bruising; bleeding, infection; severe cardiac arrhythmia (e.g. fast irregular heart 
beats); damage to the heart wall and heart valves; rupture of the pulmonary 
artery; thrombosis (formation of new blood clots); pneumothorax (collapsed 
lung); and rarely, death. The risk of serious complications is small in 
experienced centres like the one your study will be carried out in. A multicentre 
survey found the risk of such complications to be 1.1%. Your doctor will discuss 
the benefits and risks of right heart catheterisation in greater detail. You should 
be aware that you are entitled to withdraw from the study at any time. 
 
Radiation: During the right heart catheterisation, x-ray screening is used to 
check the position of the catheter. X-rays are a form of radiation which can be 
harmful. The dose of radiation you will receive during this study is equivalent to 
11 months background radiation. Background radiation is the radiation we are 
exposed to all the time from natural sources.  
 
Apelin: The study treatment, apelin, has not been used in patients with PAH 
before. It has, however been used in healthy people and in people who have 
heart failure. There have been over 130 people who have been treated with 
apelin in short studies. The doses used in this study are the same as in those 
previous studies. There were no serious adverse effects in the previous studies. 
However this does not rule out the possibility of side effects that we are not yet 
aware of, as the study treatment remains experimental. Throughout the study 
you will be continuously monitored to assess for adverse effects. 
 
Travel: You may have some distance to travel to get to the hospital for the 
study. If you require help with transport please let your study doctor know and 
arrangements can be made for this. If you require compensation for travel costs 
please discuss this with your study doctor. 
 
What if the tests reveal abnormal/unexpected findings? 
If the tests show any unexpected results, we will not proceed with the study. 
Your doctors will explain the results of the tests to you and explain why this 
excludes you from the study. Your doctors will also explain what your treatment 
options are and refer you to other specialists, if this is appropriate. 
 
What are the possible benefits of taking part? 
The study treatment will be given only for the duration of the catheter test. 
There is not yet enough information to use this as a treatment for people with 
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either PAH or heart failure. By participating in this study, important information 
regarding the effects of apelin on the lung circulation will be gathered which 
may help give us new insights into developing treatments for these conditions in 
the future. 
 
What happens when the research study stops? 
At the end of your study your specialist team will discuss the results of the 
diagnostic catheterisation test and will discuss the treatment options with you. 
Current medical treatment for PAH comprises of general strategies such as 
diuretics, digitalis, anticoagulants, and oxygen as well as specialised PAH 
specific medication like Phosphodiesterase Inhibitors (e.g. Sildenafil), Endothelin 
Receptor Antagonists (e.g. Bosentan and Ambrisentan) and Prostacyclin 
Analogues (e.g. Epoprostenol and Iloprost).  When the whole study is complete 
and the results are analysed, we will circulate a newsletter to let you know 
about the study’s progress. We will ask for your consent to do this. 
 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any 
possible harm you might suffer will be addressed. See details in part 2. 
 
Will my taking part in this study be kept confidential? 
All information regarding your participation in this study will be kept 
confidential. We will however ask for you permission to inform your GP about 
your participation in this study. 
 
 
 
If the information in part 1 has interested you and you are considering 
participation, please read the information in part 2 before making your decision. 
 
 
 
 
PART 2 
 
What will happen if I don’t want to carry on with the study? 
If you decide to take part in this study, you are free to withdraw at anytime 
without having to give a reason. If you decide to withdraw at any point in the 
study, the standard of care you will receive from your specialist PAH team will 
not be affected. 
 
What if there is a problem? 
If you have any concerns or complaints about any aspect of this study you should 
ask to speak to Prof Peacock the chief investigator of this study. If you remain 
unhappy and wish to complain formally you can do this through the NHS 
complaints procedure. Details can be obtained from your hospital. 
 
Will my taking part in this study be kept confidential? 
If you join the study, some parts of your medical records and the data collected 
for the study may be looked at by authorised persons from the study sponsors to 
ensure that the study is being carried out correctly. These people will have a 
duty of confidentiality to you as a research participant and we will do our best 
to meet this need. All information which is collected about you during the 
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course of this research will be kept strictly confidential, and any information 
which leaves the hospital will have your name and address removed so that you 
cannot be recognised. 
 
Informing your GP of your participation in this study.  
We would like to ask your permission to inform your GP about your participation 
in this study. If you agree please initial the relevant box on the consent page and 
we will send the information to your GP. 
 
 
What will happen to samples I give? 
Samples will be stored securely in a laboratory until the time that they will be 
analysed. The samples will be stored in an anonymised way. If you would like to 
know anything more about how the samples are analysed, please ask your study 
doctor. You can, at any time, get in touch with your doctor to ask for the 
samples to be destroyed. There will be no genetic analysis of your samples. 
 
What will happen to the results of the study? 
The results of the study will be analysed and published in a scientific journal, as 
well as being presented at scientific meetings. Your personal details will be 
encoded to ensure that your identity will remain confidential. 
 
Who is organising and funding the study? 
The Golden Jubilee National Hospital is the sponsor for the study. The British 
Heart Foundation has provided a grant to fund this study. 
  
Who has reviewed this study? 
The details of the study have been reviewed and approved by the West of 
Scotland Research and Ethics Committee. 
 
Contact for further information: 
 
Researcher: 
Dr Lauren Brash 
Scottish Pulmonary Vascular Unit 
Golden Jubilee National hospital 
Agamemnon Street 
Clydebank 
Glasgow 
G81 4DY 
Tel: 0141 951 5497 or 07738 569980 
Email: laurenbrash@nhs.net 
 
If you would like any further information on this study, please don’t hesitate to 
get in touch. 
 
 
Yours Sincerely, 
 
 
 
 
Professor Andrew J Peacock. 
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CONSENT FORM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Yes No 
1 I confirm that I have read and understand the patient information sheet version 5 
dated 24th January 2013 for the above study. I have had opportunity to consider 
the information, ask questions and have had these answered satisfactorily.  
 
 
 
 
 
2 I understand that my participation is voluntary and that I am free to withdraw at 
any time, without giving any reason, without my medical care and legal rights 
being affected. 
 
  
3 I understand that relevant sections of my medical notes and data collected 
during the study may be viewed by individuals involved in the study. I give 
permission for these individuals to have access to my records.  
 
  
4 I agree to participate in this study as described in the patient information sheet.   
5 I agree to blood sampling as detailed in the patient information sheet. 
 
  
6 I agree to my GP being informed of my participation in the study. 
 
  
7 I would like to receive a newsletter when the study is complete.   
8 I agree to take part in the above study.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Please initial 
relevant box 
TITLE OF STUDY:  The Effects of Apelin in Pulmonary Hypertension 
 
CHIEF INVESTIGATOR: Professor Andrew J Peacock, Scottish Pulmonary Vascular Unit,  
Golden Jubilee National Hospital, Agamemnon Street, Clydebank. G81 4DY. 
 
CONTACT: Dr Lauren Brash, Scottish Pulmonary Vascular Unit,  Golden Jubilee National 
Hospital, Agamemnon Street, Clydebank. G81 4DY. 
Tel: 0141 951 5497 or  07738 569980  Email: laurenbrash@nhs.net 
 
STUDY No.:   
 
CENTRE: Glasgow   
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One copy for investigators file. 
One copy for the patient. 
To be completed by individual taking consent: 
 
I confirm that I have explained and discussed with the patient the nature, 
purpose, requirements and risks of the study. I confirm that the patient 
has understood the information presented to them and is capable of giving 
informed consent.  
 
          
Name of Researcher   Signature   Date 
Patient: 
 
 
          
Name of Patient   Signature   Date 
PLEASE PRESCRIBE > 48 HOURS PRIOR TO TREATMENT DAY AND FAX TO PHARMACY ASEPTICS ON 34895 AND CALL TO CONFIRM 
RECIEPT ON 32625. THANK YOU. 
 
 
Study name The Effects of Apelin in Pulmonary Hypertension Prescription Sheet – APELIN-13 GOLDEN JUBILEE 
Version 3 Date 29th February 2012 
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Appendix B                       RESTING PROTOCOL PRESCRIPTION 
 
Patient name:  
Hospital number:  
Trial number:  
 
RESTING SYRINGE 1:  
Date: 
 
 
Start 
time: 
Concentration: 
 
10 
nanomol/ml 
Flow rate 
setting: 
 
1 ml/min 
Total Volume infused: 
 
……………….of 15 mLs 
Prescribed by: 
 
 
 …………………………… 
Administered by: 
 
 
…………………………… 
RESTING SYRINGE 2:  
Date: 
 
 
Start 
time: 
Concentration: 
 
30 
nanomol/ml 
Flow rate 
setting: 
 
1 ml/min 
Total Volume infused: 
 
……………….of 15 mLs 
Prescribed by: 
 
 
 …………………………… 
Administered by: 
 
 
…………………………… 
RESTING SYRINGE 3:  
Date: 
 
 
Start 
time: 
Concentration: 
 
100 
nanomol/ml 
Flow rate 
setting: 
 
1 ml/min 
Total Volume infused: 
 
…………….of 13.5 mLs 
Prescribed by: 
 
 
 …………………………… 
Administered by: 
 
 
…………………………… 
WASHOUT PERIOD 
 
 
 
 
 
 
 
Required by:  
Call when ready:  
PLEASE PRESCRIBE > 48 HOURS PRIOR TO TREATMENT DAY AND FAX TO PHARMACY ASEPTICS ON 34895 AND CALL TO CONFIRM 
RECIEPT ON 32625. THANK YOU. 
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RESTING SYRINGE 4: 
Date: 
 
 
Start 
time: 
Concentration: 
 
10 
nanomol/ml 
Flow rate 
setting: 
 
1 ml/min 
Total Volume infused: 
 
…………….of 15 mLs 
Prescribed by: 
 
 
 …………………………… 
Administered by: 
 
 
…………………………… 
RESTING SYRINGE 5: 
Date: 
 
 
Start 
time: 
Concentration: 
 
30 
nanomol/ml 
Flow rate 
setting: 
 
1 ml/min 
Total Volume infused: 
 
…………….of 15 mLs 
Prescribed by: 
 
 
 …………………………… 
Administered by: 
 
 
…………………………… 
RESTING SYRINGE 6:  
Date: 
 
 
Start 
time: 
Concentration: 
 
100 
nanomol/ml 
Flow rate 
setting: 
 
1 ml/min 
Total Volume infused: 
 
…………….of 13.5 mLs 
Prescribed by: 
 
 
 …………………………… 
Administered by: 
 
 
…………………………… 
 
 
 
 
 
 
 
 
 
 
PLEASE PRESCRIBE > 48 HOURS PRIOR TO TREATMENT DAY AND FAX TO PHARMACY ASEPTICS ON 34895 AND CALL TO CONFIRM 
RECIEPT ON 32625. THANK YOU. 
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EXERCISE PROTOCOL PRESCRIPTION 
 
Patient name:  
Hospital number:  
Trial number:  
 
EXERCISE SYRINGE 1:  
Date: 
 
 
Start 
time: 
Concentration: 
 
10 
nanomol/ml 
Flow rate 
setting: 
 
1 ml/min 
Total Volume infused: 
 
……………….of 15 mLs 
Prescribed by: 
 
 
 …………………………… 
Administered by: 
 
 
…………………………… 
EXERCISE SYRINGE 2:  
Date: 
 
 
Start 
time: 
Concentration: 
 
30 
nanomol/ml 
Flow rate 
setting: 
 
1 ml/min 
Total Volume infused: 
 
……………….of 15 mLs 
Prescribed by: 
 
 
 …………………………… 
Administered by: 
 
 
…………………………… 
EXERCISE SYRINGE 3:  
Date: 
 
 
Start 
time: 
Concentration: 
 
100 
nanomol/ml 
Flow rate 
setting: 
 
1 ml/min 
Total Volume infused: 
 
…………….of 26.7 mLs 
Prescribed by: 
 
 
 …………………………… 
Administered by: 
 
 
…………………………… 
WASHOUT PERIOD 
 
 
 
 
 
Required by:  
Call when ready:  
PLEASE PRESCRIBE > 48 HOURS PRIOR TO TREATMENT DAY AND FAX TO PHARMACY ASEPTICS ON 34895 AND CALL TO CONFIRM 
RECIEPT ON 32625. THANK YOU. 
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EXERCISE SYRINGE 4: 
Date: 
 
 
Start 
time: 
Concentration: 
 
10 
nanomol/ml 
Flow rate 
setting: 
 
1 ml/min 
Total Volume infused: 
 
……………….of 15 mLs 
Prescribed by: 
 
 
 …………………………… 
Administered by: 
 
 
…………………………… 
EXERCISE SYRINGE 5: 
Date: 
 
 
Start 
time: 
Concentration: 
 
30 
nanomol/ml 
Flow rate 
setting: 
 
1 ml/min 
Total Volume infused: 
 
……………….of 15 mLs 
Prescribed by: 
 
 
 …………………………… 
Administered by: 
 
 
…………………………… 
EXERCISE SYRINGE 6:  
Date: 
 
 
Start 
time: 
Concentration: 
 
100 
nanomol/ml 
Flow rate 
setting: 
 
1 ml/min 
Total Volume infused: 
 
……………of 26.7 mLs 
Prescribed by: 
 
 
 …………………………… 
Administered by: 
 
 
…………………………… 
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The Effects of Apelin in Pulmonary Hypertension – Infusion 
Preparation Guide : Resting Protocol 
 
 
This document describes the process of preparing the infusions for the study: 
‘The effects of Apelin in Pulmonary Hypertension.’ If there are any questions 
please contact the Chief Investigator. 
 
Contact: 
Dr Lauren Brash  
(on behalf of Prof. A Peacock) 
Scottish Pulmonary Vascular Unit 
Golden Jubilee National Hospital 
Agamemnon Street 
Clydebank 
Glasgow 
G81 4DY 
 
Tel: 0141 951 5497 
Mob: 07738 569980 
Email: laurenbrash@nhs.net 
 
 
 
Apelin Infusions 
Equipment Required: 
 
• 3x vials Bachem Apelin-13 
• 50 mls 0.9% sodium Chloride 
• Graseby 2000 syringe pump (or equivalent. Check what size syringes are compatible) 
– Set to deliver 1ml/minute. 
• 3x IV extension set 
• leur lock syringes – 5mls/10mls/20mls/30mls/50mls 
• hypodermic needles 
• Sterile disposable drape 
• Sterile gloves 
• Red combi syringe stoppers (or equivalent) 
• Pre-prepared ‘Exercise’ syringe labels 
• Someone to prepare vials and someone to check preparation 
 
Instructions 
Primary Stock Solution:         300 nanomol/ml 
 
1. Lay disposable sterile drape over clean work surface, clean hands and 
use sterile gloves to prepare Apelin infusion. 
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2. Draw up 6.5 mls of 0.9% sodium chloride in 10 mls Syringe. 
3. Distribute the 6.5 mls between the 3 vials of lyophilised Apelin. (2.2 mls 
in 2 vials, 2.1 mls in the third.) 
4. Aspirate the solution from all 5 vials back into the syringe. 
5. This syringe should be labelled ‘PRIMARY STOCK SOLUTION’ and contains 
6.5 mls of Apelin-13 at a concentration of 300 nanomol/ml.  
 
First dilution step:            ******SECOND INFUSION******      30 nanomol/ml 
 
1. Using 20 -50 mls syringe (if this is compatible with syringe pump) 
aspirate 13.5 mls of 0.9% sodium chloride. 
2. Using 5 mls syringe aspirate 1.5 mls of ‘PRIMARY STOCK SOLUTION’ and 
add this to 20 mls syringe containing 13.5 mls of 0.9% Sodium Chloride. 
3. Put combi stopper (red cap or equivalent) onto the tip of the syringe and 
ensure solution is thoroughly mixed. 
4. This syringe now contains 15mls of Apelin-13 at a concentration of 30 
nanomol/ml. 
5. Label this syringe with prepared sticker ‘RESTING APELIN SYRINGE 2’ 
6. Attach IV extension set to tip of syringe and manually prime the line 
ensuring there is no loss of Apelin. 
7. ‘RESTING APELIN SYRINGE 2’ is ready for use. 
 
Secondary Stock Solution:                                                                    100 
nanomol/ml 
 
1. Using a 20 - 50 mls syringe (if this is compatible with syringe pump) 
aspirate 10 mls of 0.9% sodium chloride. 
2. Add the remaining ‘PRIMARY STOCK SOLUTION’ to the 10 mls. There 
should be 5 mls. The final volume will be 15 mls.  
3. Put combi stopper (red cap or equivalent) onto the tip of the syringe and 
ensure solution is thoroughly mixed. 
4. This syringe should be labelled ‘SECONDARY STOCK SOLUTION’ and 
contains 15 mls of Apelin-13 at a concentration of 100 nanomol/ml. 
 
Second dilution step:          ******FIRST INFUSION******             10 nanomol/ml 
 
1. Using a 20 - 50 mls syringe (if this is compatible with syringe pump) 
aspirate 13.5 mls of 0.9% sodium chloride. 
2. Using 5 mls syringe aspirate 1.5 mls of ‘SECONDARY STOCK SOLUTION’ 
and add this to 20 mls syringe containing 13.5 mls of 0.9% Sodium 
Chloride. 
3. Put combi stopper (red cap or equivalent) onto the tip of the syringe and 
ensure solution is thoroughly mixed. 
4. This syringe now contains 15mls of Apelin-13 at a concentration of 10 
nanomol/ml. 
5. Label this syringe with prepared sticker ‘RESTING APELIN SYRINGE 1’ 
  Study name The Effects of Apelin in Pulmonary Hypertension Infusion Preparation Guide: Resting protocol 
Version 2 Date 25th Feb 2013 
6. Attach IV extension set to tip of syringe and manually prime the line 
ensuring there is no loss of Apelin. 
7. ‘RESTING APELIN SYRINGE 1’ is ready for use. 
 
Final step:                         ******THIRD INFUSION******             100 nanomol/ml 
 
1. The 20 - 50 mls syringe labelled ‘SECONDARY STOCK SOLUTION’ should 
now contain 13.5 mls of Apelin-13 at a concentration of 100 
nanomol/ml. 
2. Label this syringe with prepared sticker ‘RESTING APELIN SYRINGE 3’ 
3. Attach IV extension set to tip of syringe and manually prime the line 
ensuring there is no loss of Apelin. 
4. ‘RESTING APELIN SYRINGE 3’ is ready for use. 
 
Final Product: 
 
1. ‘RESTING APELIN SYRINGE 1’. Syringe containing 15 mls of Apelin-13 at a 
concentration of 10 nanomol/ml. 
 
2. ‘RESTING APELIN SYRINGE 2’. Syringe containing 15 mls of Apelin-13 at a 
concentration of 30 nanomol/ml. 
 
3. ‘RESTING APELIN SYRINGE 3’. Syringe containing 13.5 mls of Apelin-13 at 
a concentration of 100 nanomol/ml 
 
 
 
 
 
Saline Infusions 
Equipment Required: 
 
• 50 mls 0.9% sodium Chloride 
• 3x IV extension set 
• leur lock syringes – 5mls/20mls/30mls/50mls 
• hypodermic needles 
• Sterile disposable drape 
• Sterile gloves 
• Red combi syringe stoppers (or equivalent) 
• Pre-prepared ‘Exercise’ syringe labels 
 
Placebo Infusion 1:  
 
1. Aspirate 15mls of 0.9% sodium chloride into a 20 - 50 mls syringe (if this is 
compatible with syringe pump). 
2. Label this syringe with prepared sticker ‘RESTING SALINE SYRINGE 1’ 
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3. Attach IV extension set to tip of syringe and manually prime the line 
ensuring there is no loss of Saline. 
 
Placebo Infusion 2: 
 
1. Aspirate 15mls of 0.9% sodium chloride into a 20 - 50 mls syringe (if this is 
compatible with syringe pump). 
2. Label this syringe with prepared sticker ‘RESTING SALINE SYRINGE 2’ 
3. Attach IV extension set to tip of syringe and manually prime the line 
ensuring there is no loss of Saline. 
 
Placebo Infusion 3:  
 
1. Aspirate 13.5 mls of 0.9% sodium chloride into a 20 - 50 mls syringe (if this is 
compatible with syringe pump). 
2. Label this syringe with prepared sticker ‘RESTING SALINE SYRINGE 3’ 
3. Attach IV extension set to tip of syringe and manually prime the line 
ensuring there is no loss of Saline. 
 
Final Product:  
 
1. ‘RESTING SALINE SYRINGE 1’ Syringe containing 15mls of 0.9% sodium 
chloride. 
2. ‘RESTING SALINE SYRINGE 2’ Syringe containing 15mls of 0.9% sodium 
chloride. 
3. ‘RESTING SALINE SYRINGE 3’ Syringe containing 13.5 mls of 0.9% sodium 
chloride. 
 
 
 
Infusion protocol 
 
 
• Someone who is not carrying out the right heart catheter and who is not 
recording the data will need to be unblinded to the study. 
• Prior to the procedure they should contact Val Pollock via the protocol to 
establish the order of infusion. 
• This will either be ‘Apelin then Saline placebo’ or ‘Saline placebo then 
Apelin’. 
• They will then start each infusion when required. 
• If the order is ‘Apelin then Saline placebo’ they will deliver the syringes 
in the following order: 
 ‘RESTING APELIN SYRINGE 1’ 
 ‘RESTING APELIN SYRINGE 2’ 
 ‘RESTING APELIN SYRINGE 3’  
 Then 30 minute washout period before: 
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 ‘RESTING SALINE SYRINGE 1’ 
 ‘RESTING SALINE SYRINGE 2’ 
 ‘RESTING SALINE SYRINGE 3’ 
• If the order is ‘Saline placebo then Apelin’ they will deliver the syringes 
in the following order: 
 ‘RESTING SALINE SYRINGE 1’ 
 ‘RESTING SALINE SYRINGE 2’ 
 ‘RESTING SALINE SYRINGE 3’  
 Then 30 minute washout period before: 
 ‘RESTING APELIN SYRINGE 1’ 
 ‘RESTING APELIN SYRINGE 2’ 
 ‘RESTING APELIN SYRINGE 3’  
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The Effects of Apelin in Pulmonary Hypertension – Infusion 
Preparation Guide : Exercise Protocol 
 
 
This document describes the process of preparing the infusions for the study: 
‘The effects of Apelin in Pulmonary Hypertension.’ If there are any questions 
please contact the Chief Investigator. 
 
Contact: 
Dr Lauren Brash  
(on behalf of Prof. A Peacock) 
Scottish Pulmonary Vascular Unit 
Golden Jubilee National Hospital 
Agamemnon Street 
Clydebank 
Glasgow 
G81 4DY 
 
Tel: 0141 951 5497 
Mob: 07738 569980 
Email: laurenbrash@nhs.net 
 
 
 
Apelin Infusions 
Equipment Required: 
 
• 5x vials Bachem Apelin-13 
• 50 mls 0.9% sodium Chloride 
• Graseby 2000 syringe pump (or equivalent. Check what size syringes are compatible) 
– Set to deliver 1ml/minute. 
• 3x IV extension set 
• leur lock syringes – 5mls/20mls/30mls/50mls 
• hypodermic needles 
• Sterile disposable drape 
• Sterile gloves 
• Red combi syringe stoppers (or equivalent) 
• Pre-prepared ‘Exercise’ syringe labels 
• Someone to prepare vials and someone to check preparation 
 
Instructions 
Primary Stock Solution:         300 nanomol/ml 
 
6. Lay disposable sterile drape over clean work surface, clean hands and 
use sterile gloves to prepare Apelin infusion. 
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7. Draw up 10.9 mls of 0.9% sodium chloride in 20 mls Syringe. 
8. Distribute the 10.9 mls between the 5 vials of lyophilised Apelin. (2.2 
mls in 4 vials, 2.1 mls in the fifth.) 
9. Aspirate the solution from all 5 vials back into syringe. 
10. This syringe should be labelled ‘PRIMARY STOCK SOLUTION’ and contains 
10.9 mls of Apelin-13 at a concentration of 300 nanomol/ml.  
 
First dilution step:            ******SECOND INFUSION******      30 nanomol/ml 
 
8. Using 20 - 50 mls syringe (if this is compatible with syringe pump) 
aspirate 13.5 mls of 0.9% sodium chloride. 
9. Using 5 mls syringe aspirate 1.5 mls of ‘PRIMARY STOCK SOLUTION’ and 
add this to 20 mls syringe containing 13.5 mls of 0.9% Sodium Chloride. 
10. Put combi stopper (red cap or equivalent) onto the tip of the syringe and 
ensure solution is thoroughly mixed. 
11. This syringe now contains 15mls of Apelin-13 at a concentration of 30 
nanomol/ml. 
12. Label this syringe with prepared sticker ‘EXERCISE APELIN SYRINGE 2’ 
13. Attach IV extension set to tip of syringe and manually prime the line 
ensuring there is no loss of Apelin. 
14. ‘EXERCISE APELIN SYRINGE 2’ is ready for use. 
 
Secondary Stock Solution:                                                                    100 
nanomol/ml 
 
5. Using a 30 – 50 mls syringe (if this is compatible with syringe pump) 
aspirate 18.8 mls of 0.9% sodium chloride. 
6. Add the remaining ‘PRIMARY STOCK SOLUTION’ to the 18.8 mls. There 
should be 9.4 mls. The final volume will be 28.2 mls.  
7. Put combi stopper (red cap or equivalent) onto the tip of the syringe and 
ensure solution is thoroughly mixed. 
8. This syringe should be labelled ‘SECONDARY STOCK SOLUTION’ and 
contains 28.2 mls of Apelin-13 at a concentration of 100 nanomol/ml. 
 
Second dilution step:          ******FIRST INFUSION******             10 nanomol/ml 
 
8. Using 20 - 50 mls syringe (if this is compatible with syringe pump) 
aspirate 13.5 mls of 0.9% sodium chloride. 
9. Using 5 mls syringe aspirate 1.5 mls of ‘SECONDARY STOCK SOLUTION’ 
and add this to 20 mls syringe containing 13.5 mls of 0.9% Sodium 
Chloride. 
10. Put combi stopper (red cap or equivalent) onto the tip of the syringe and 
ensure solution is thoroughly mixed. 
11. This syringe now contains 15mls of Apelin-13 at a concentration of 10 
nanomol/ml. 
12. Label this syringe with prepared sticker ‘EXERCISE APELIN SYRINGE 1’ 
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13. Attach IV extension set to tip of syringe and manually prime the line 
ensuring there is no loss of Apelin. 
14. ‘EXERCISE APELIN SYRINGE 1’ is ready for use. 
 
Final step:                         ******THIRD INFUSION******             100 nanomol/ml 
 
5. The 30 - 50 mls syringe labelled ‘SECONDARY STOCK SOLUTION’ should 
now contain 26.7 mls of Apelin-13 at a concentration of 100 
nanomol/ml. 
6. Label this syringe with prepared sticker ‘EXERCISE APELIN SYRINGE 3’ 
7. Attach IV extension set to tip of syringe and manually prime the line 
ensuring there is no loss of Apelin. 
8. ‘EXERCISE APELIN SYRINGE 3’ is ready for use. 
 
Final Product: 
 
4. ‘EXERCISE APELIN SYRINGE 1’. Syringe containing 15 mls of Apelin-13 at a 
concentration of 10 nanomol/ml. 
 
5. ‘EXERCISE APELIN SYRINGE 2’. Syringe containing 15 mls of Apelin-13 at a 
concentration of 30 nanomol/ml. 
 
6. ‘EXERCISE APELIN SYRINGE 3’. Syringe containing 26.7 mls of Apelin-13 
at a concentration of 100 nanomol/ml 
 
 
 
 
 
 
 
Saline Infusions 
Equipment Required: 
 
• 50 mls 0.9% sodium Chloride 
• 3x IV extension set 
• leur lock syringes – 5mls/20mls/30mls/50mls 
• hypodermic needles 
• Sterile disposable drape 
• Sterile gloves 
• Red combi syringe stoppers (or equivalent) 
• Pre-prepared ‘Exercise’ syringe labels 
 
Placebo Infusion 1:  
 
4. Aspirate 15mls of 0.9% sodium chloride into a 20 - 50 mls syringe (if this is 
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compatible with syringe pump). 
5. Label this syringe with prepared sticker ‘EXERCISE SALINE SYRINGE 1’ 
 
Placebo Infusion 2: 
 
4. Aspirate 15mls of 0.9% sodium chloride into a 20 - 50 mls syringe (if this is 
compatible with syringe pump). 
5. Label this syringe with prepared sticker ‘EXERCISE SALINE SYRINGE 2’ 
 
Placebo Infusion 3:  
 
4. Aspirate 26.7 mls of 0.9% sodium chloride into a 30 - 50 mls syringe (if this is 
compatible with syringe pump). 
5. Label this syringe with prepared sticker ‘EXERCISE SALINE SYRINGE 3’ 
 
Final Product:  
 
4. ‘EXERCISE SALINE SYRINGE 1’ Syringe containing 15mls of 0.9% sodium 
chloride. 
5. ‘EXERCISE SALINE SYRINGE 2’ Syringe containing 15mls of 0.9% sodium 
chloride. 
6. ‘EXERCISE SALINE SYRINGE 3’ Syringe containing 26.7mls of 0.9% sodium 
chloride. 
 
 
 
 
 
 
 
Infusion protocol 
 
 
• Someone who is not carrying out the right heart catheter and who is not 
recording the data will need to be unblinded to the study. 
• Prior to the procedure they should contact Val Pollock via the protocol to 
establish the order of infusion. 
• This will either be ‘Apelin then Saline placebo’ or ‘Saline placebo then 
Apelin’. 
• They will then start each infusion when required. 
• If the order is ‘Apelin then Saline placebo’ they will deliver the syringes 
in the following order: 
 ‘EXERCISE APELIN SYRINGE 1’ 
 ‘EXERCISE APELIN SYRINGE 2’ 
 ‘EXERCISE APELIN SYRINGE 3’ (with exercise) 
 Then 30 minute washout period before: 
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 ‘EXERCISE SALINE SYRINGE 1’ 
 ‘EXERCISE SALINE SYRINGE 2’ 
 ‘EXERCISE SALINE SYRINGE 3’ (with exercise) 
• If the order is ‘Saline placebo then Apelin’ they will deliver the syringes 
in the following order: 
 ‘EXERCISE SALINE SYRINGE 1’ 
 ‘EXERCISE SALINE SYRINGE 2’ 
 ‘EXERCISE SALINE SYRINGE 3’ (with exercise) 
 Then 30 minute washout period before: 
 ‘EXERCISE APELIN SYRINGE 1’ 
 ‘EXERCISE APELIN SYRINGE 2’ 
 ‘EXERCISE APELIN SYRINGE 3’ (with exercise) 
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Study Title: Acute Pulmonary Haemodynamic Effects of Apelin in Pulmonary Hypertension 
 
Investigator: Prof. A Peacock      PI:       Centre:   
 
 
 
 
    Drug: 
(Pyr1)-Apelin-13 (human) 
Acetate  
Clinalfa basic 
Molecular 
Weight: 
 
1533.8 g/mol 
Weight: 
 
1.0 
mg/vial 
 
 
Lyophilised 
 
Certificate of 
Analysis 
enclosed 
 Apelin-
13 
received 
Apelin-13 dispensed Apelin-13 
destroyed 
Apelin-
13 in 
Stock 
 
No. of 
Vials 
Patient ID No. of 
Vials 
No. of 
Vials 
Total 
No. of 
Vials 
Date Batch No. N/A if not applicable Name/ Signature Comments 
         
         
         
         
         
         
         
         
         
         
Apelin Data Collection Proforma 
 
 
Appendix C 
 
 
 Baseline Data Inhaled NO  
    
Time       
Load Unloaded Unloaded Unloaded Unloaded Unloaded Unloaded 
Watts       
Infusion rate (nmol/min) No Infusion No Infusion No Infusion No Infusion No Infusion No Infusion 
Blood Sampling       
 FiO2       
SaO2       
Heart Rate       
 
Systemic BP 
Syst 
Diast 
Mean 
      
      
      
SVR (dyns) 
SVR (WU) 
      
      
RAP (mean)       
RVP (systolic)       
RVEDP       
Pulmonary artery pressure Syst 
Diast 
Mean 
      
      
      
PAWP       
 
Transpulm gradient       
Fick CO (Q systemic)       
Cardiac output (L/min)       
Cardiac index       
PVR (Wood units)       
PVR Index       
TPR       
Stroke Volume (ml)       
Stroke Volume Index       
Capacitance index       
SvO2 (main PA)       
Patient Study Number:  
 Date: Approach: 
Study centre:  
Operators: 
Age: 
Body surface area (m2): 0.00 
 
Measured VO2 (mL/min): 
Gender  
Height (m): 
Estimated VO2: 
Hb (g/dl) 
Weight (kg): 
BMI (kg/m²): 
Apelin Data Collection Proforma 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 Resting  Exercise 
 Infusion A 
Time        
Load Unloaded Unloaded Unloaded Unloaded Legs Raised 20% 40% 
Watts        
Infusion rate (nmol/min) 0 10 30 100 100 100 100 
Blood Sampling        
 FiO2        
SaO2        
Heart Rate        
 
Systemic BP 
Syst 
Diast 
Mean 
       
       
       
SVR (dyns) 
SVR (WU) 
       
       
RAP (mean)        
RVP (systolic)        
RVEDP        
Pulmonary 
artery pressure 
Syst 
Diast 
Mean 
       
       
       
PAWP        
 
Transpulm gradient        
Fick CO (Q systemic)        
Cardiac output (L/min)        
Cardiac index        
PVR (Wood units)        
PVR Index        
TPR        
Stroke Volume (ml)        
Stroke Volume Index        
Capacitance index        
SvO2 (main PA)        
Comments  
Apelin Data Collection Proforma 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 Washout - 30 Minutes Resting Data 
   
Time       
Load Unloaded Unloaded Unloaded Unloaded Unloaded Unloaded 
Watts       
Infusion rate (nmol/min) 0 0 0 0 0 0 
Blood Sampling       
 FiO2       
SaO2       
Heart Rate       
 
Systemic BP 
Syst 
Diast 
Mean 
      
      
      
SVR (dyns) 
SVR (WU) 
      
      
RAP (mean)       
RVP (systolic)       
RVEDP       
Pulmonary 
artery pressure 
Syst 
Diast 
Mean 
      
      
      
PAWP       
 
Transpulm gradient       
Fick CO (Q systemic)       
Cardiac output (L/min)       
Cardiac index       
PVR (Wood units)       
PVR Index       
TPR       
Stroke Volume (ml)       
Stroke Volume Index       
Capacitance index       
SvO2 (main PA)       
Comments  
Apelin Data Collection Proforma 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 Resting  Exercise 
 Infusion B 
Time       
Load Unloaded Unloaded Unloaded Unloaded Legs Raised 20% 40% 
Watts        
Infusion rate (nmol/min) 0 10 30 100 100 100 100 
Blood Sampling       
 
FiO2        
SaO2        
Heart Rate        
 
Systemic BP 
Syst 
Diast 
Mean 
       
       
       
SVR (dyns) 
SVR (WU) 
       
       
RAP (mean)        
RVP (systolic)        
RVEDP        
Pulmonary 
artery pressure 
Syst 
Diast 
Mean 
       
       
       
PAWP        
 
Transpulm gradient        
Fick CO (Q systemic)        
Cardiac output (L/min)        
Cardiac index        
PVR (Wood units)        
PVR Index        
TPR        
Stroke Volume (ml)        
Stroke Volume Index        
Capacitance index        
SvO2 (main PA)        
Comments  
Apelin Data Collection Proforma 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 Extra Data Sheet  
  
Time       
Load       
Watts       
Infusion rate (nmol/min)       
Blood Sampling       
 FiO2       
SaO2       
Heart Rate       
 
Systemic BP 
Syst 
Diast 
Mean 
      
      
      
SVR (dyns) 
SVR (WU) 
      
      
RAP (mean)       
RVP (systolic)       
RVEDP       
Pulmonary 
artery pressure 
Syst 
Diast 
Mean 
      
      
      
PAWP       
Transpulm gradient       
Fick CO (Q systemic)       
Cardiac output (L/min)       
Cardiac index       
PVR (Wood units)       
PVR Index       
TPR       
Stroke Volume (ml)       
Stroke Volume Index       
Capacitance index       
SvO2 (main PA)       
Comments  
 AA 
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Haemodynamic Effects of Apelin in 
Pulmonary Hypertension  
 
Protocol Manual 
 
 
Pulmonary Arterial Hypertension Cohort 
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Study Contacts and References 
 
Contact Role Address/Number 
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 1. Identifying Study participants 
  
 
1.1 Screening 
 
Patients will be identified as potential study participants when attending clinic 
for review or when admitted to the ward for diagnostic investigation of probable 
idiopathic pulmonary arterial hypertension (IPAH). 
 
The recruitment checklist will be used to identify if patient meets 
inclusion/exclusion criteria. They will need to have had previous 
echocardiogram, bloods, pulmonary function tests and CT scan to establish 
whether they meet recruitment criteria. 
 
If attending for diagnostic investigations they will be recruited and consented on 
the proviso that during the diagnostic right heart catheterisation (RHC) they will 
meet all the inclusion criteria thus allowing continuation into the study protocol. 
 
 
1.2 Consenting 
 
If the patient meets all the inclusion criteria (or all inclusion criteria other than 
impending RHC criteria) the patient will be offered participation into trial. They 
should be given a patient information sheet and allowed at least 24 hours to 
consider the information prior to consent being obtained. Patients who are on 
warfarin may give verbal consent over the phone to stop warfarin. They should 
have read the patient information sheet and have had a member of the study 
team explain the consequences of stopping warfarin. 
 
 
1.3 Cardiopulmonary exercise testing 
 
In the lead up to the study, the participant should undergo an erect maximal 
incremental cardiopulmonary exercise test (CPET) to establish their maximum 
workload. This will allow calculation of the workload required during the 
exercise component of the study protocol. If the subject is unsuitable for the 
exercise component of the study this step can be omitted.  
 
 
1.4 Randomisation 
 
The IPAH participants will be allocated a study number from 301 to 321. Each 
study number has been randomly allocated an infusion order. They will either 
receive Apelin as Infusion A then Placbo as Infusion B or vice versa. Participants 
for the IPAH cohort will be recruited at two sites; Hammersmith and Glasgow. 
There is one contact who will allocate the study number and randomisation 
order for recruits at both sites. This is Val Pollock, clinical trials nurse at 
Glasgow. Once a participant has been recruited, a member of the study team 
should contact Val to receive their study number and Infusion order. Contact 
should be made at least a few days before the study is planned via email if 
possible. The person who collects this information will be unblinded and should 
not be involved in collecting data. 
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  Val Pollock 
 Scottish Pulmonary Vascular Unit 
 Golden Jubilee National Hospital 
Agamemnon Street 
Clydebank 
Glasgow 
G81 4DY 
 
Tel: 0141 951 5485 
Email: val.pollock@gjnh.scot.nhs.uk 
 
   
1.5 Intravenous access 
 
Study participants will require a peripheral intravenous cannula (preferably 20G 
or 18G) to allow administration of the infusions. This should not be in the same 
arm as the sphygmomanometer cuff that will be used during RHC to measure 
systemic BP. 
 
 
1.6 Introducer sheath 
 
A sheath will be inserted as is usual procedure for RHC. In order to allow the 
possibility of the exercise component of the protocol to be carried out, this 
should preferably be in the internal jugular vein. And the femoral veins should 
be avoided. 
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2. Apelin 
 
 
2.1 Ordering/Transport 
 
The Apelin is provided by Bachem Clinalfa basic and is approved for use in 
clinical trials. Each vial contains 1mg. Depending on whether exercise is planned 
or not each study will require either 5 or 3 vials. 
 
Bachem have agreed to deliver the Apelin in 3 batches. Each batch is 
transported in  -20C conditions. There is a temperature logger with each 
delivery and this must be downloaded and returned to Bachem who will analyse 
the data and notify the units regarding whether the delivery is safe for use. It 
can be arranged for Apelin to be delivered between sites if necessary. When a 
delivery is received it should be logged in the drug accountability document. 
 
If stocks are running low please get in touch with Dr Lauren Brash to order more 
Apelin. 
 
There is a Certificate of Analysis and transmissible spongi-form encephalopathy 
(TSE) certificate with each delivery. 
 
 
2.2 Storage 
 
Apelin should be stored at -20°C when it arrives in pharmacy until it is used. 
 
 
2.3 Preparation/Labelling 
 
The Apelin should be collected from pharmacy at least 30 minutes before use, to 
allow time for it to defrost at room temperature.  
 
5 vials will be required if exercise is planned. 3 vials will be required if no 
exercise is planned. The Apelin can be requested using the Apelin request form 
and will be logged in the Drug Accountability document.  
 
Please follow the appropriate Infusion Preparation document for further 
guidance on preparing the infusions.  
 
Labels will be provided for each infusion. If more labels are required, please 
contact Dr Lauren Brash 
 
 
 
2.4 Infusion 
 
Infusion of both Apelin and 0.9% sodium chloride placebo should be via a Graseby 
Pump (or equivalent) set at 1ml/min. The infusion line will need to be primed 
manually with 1 mL of the solution. The pump automatically stops with 1 mL left 
to infuse. Therefore the infusion time of each syringe is 2 minutes less than 
expected. 
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An unblinded person at each site will have received the randomisation order and 
will label the 6 syringes as infusion A (10, 30, 100 nanomol/mL) or Infusion B 
(10, 30, 100 nanomol/mL).  
 
Infusion A should be given in sequential order. There will then be a 30 minute 
washout period before Infusion B is delivered in sequential order. 
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3. Data Collection 
 
 
3.1  Clinical enrolment proforma 
 
There is a clinical enrolment proforma and a data collection proforma. 
 
Once a patient has been identified as a potential study participant, the clinical 
enrolment proforma should be completed. This will document the relevant 
inclusion and exclusion variables to ensure they are appropriate for the study. 
 
3.2 Data collection proforma 
 
All data during the cath lab study should be collected on the provided data 
collection proforma.  
 
The person carrying out the RHC and collecting the data should be blinded to the 
infusion order. (ie whether Infusion A is placebo or Apelin.) 
 
Initially diagnostic RHC data will be collected including heart rate (HR), systemic 
blood pressure (BP), right atrial pressure (RAP), right ventricular pressure (RVP), 
right ventricular end-diastolic pressure (RVEDP), pulmonary artery pressure 
(PAP), pulmonary artery wedge pressure (PAWP) and cardiac outputs. Nitric 
oxide should be given as per standard protocol if this is a diagnostic assessment. 
 
3.3 Order of data collection 
 
Infusion A at 10 nanomol/mL should be put in the Grasby Pump set to deliver the 
infusion at 1 mL/min. A timer should be set and data collection should start at 5 
mins.  
 
Data to be collected is: 
 
 mean PAP, PAWP, CO x2, mean PAP, HR then manual systemic BP  
(so that cuff doesn’t cause increase in any other pressure measurements) 
 
This should be repeated with Infusion A at 30 nanomol/mL. 
 
Then repeated with Infusion A at 100 nanomol/mL. 
 
After the resting data is collected the third infusion should be paused to allow 
time to get the supine ergometer into position on the procedure table. Once this 
is in position with the participants feet strapped into the pedals the third 
infusion should be restarted. Initally the infusion should be delivered while the 
participant rests with their feet elevated in the pedals. The same data (above in 
bold)  should be collected at 5 minutes.  
The participant should then start cycling at 20% of their maximal erect CPET 
workload. After 2 minutes of cycling further data should be collected (the 
participant should continue exercise while this is collected). 
The workload should be increased to 40% of their maximal erect CPET workload 
and after a further 2 minute of cycling further data should be collected. 
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A 30 minute washout/rest period is then required before carrying out the same 
protocol for Infusion B. 
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4. Blood Samples 
 
 
Blood samples should be collected just prior to starting both infusion A and 
Infusion B and immediately post exercise (or if no exercise, at the end of the 
infusion period) for each infusion. 
 
There should be 1 x EDTA bottle (4ml) and 2 x serum separating bottles (5ml) 
collected at each time point.  The EDTA bottles with the blood should be placed 
immediately on ice on withdrawal from the vein. The SST bottles with bloods 
will be allowed to stand at room temperature for 30mins – 60mins before 
processing. Both samples should be processed within 1hour after collection.The 
samples should be taken via the 3 way tap on the side arm of the IJV sheath. 
 
The EDTA  samples should be spun in a centrifuge at 4000rpm for 15 mins at 4◦ C. 
The SST samples should be spun at the same centrifuge setting as the EDTA but 
at room temperature ( between 18◦C -20◦C).  Each  plasma Sample (EDTA) and 
serum samples (SST) should then be aliquoted  in two 1.5ml eppendorfs storage 
tubes and  then stored at -80°C until the end of the study.  
 
The collection tubes should be labelled:    
 
Study No:….  Date….. Pre-Inf A.  (EDTA) 
Study No:….  Date….. Pre-Inf A.  (SST) 
Study No:….  Date….. Pre-Inf A.  SST 
       
Study No:….  Date….. Post-Inf A.( EDTA) 
Study No:….  Date….. Post-Inf A. (SST_) 
Study No:….  Date….. Post-Inf A. (SST) 
 
The same should be done for the samples collected during Infusion B. 
 
The Eppendorf tubes should be labelled as above however there should be two 
1.5 ml for each colletion tube at each time-point for infusion A and infusion B. 
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5. Unblinding Procedure 
 
 
The principal Investigator at each site will determine whether there is any 
reason for a particular study to be unblinded. If they establish this to be the 
case, they can approach the unblinded person on site who can provide the 
infusion details. Any unblinding should be reported to the Chief Investigator with 
details of the reason for unblinding as soon as possible. 
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6. Progress Reporting 
 
 
In order to provide the study sponsor with recruitment updates, Dr Lauren Brash 
will email each centre at the end of each month to confirm recruitment 
numbers. If there have been and serious adverse events (SAEs) these will need to 
be reported also.  
 
The information the sponsor requires is:  
 
 Total recruitment numbers for the month 
 Patient study ID numbers for the month 
 Dates of recruitment 
 SAE reports 
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Appendix E            (Clinical Services Division) 
 
DEPARTMENT OF CLINICAL PHYSICS AND BIO-ENGINEERING 
Health Physics Service 
West House (Ground Floor) 
Gartnavel Royal Hospital        Telephone:     0141 211 3428 
1055 Great Western Road        Fax:                0141 211 6761 
Glasgow  G12 OXH           E-mail:         andy.brennan@ggc.scot.nhs.uk 
 
memorandum 
    
To: Prof A Peacock 
Scottish Pulmonary Vascular Unit,  
GJNH 
 
From: 
 
Mr A G Brennan 
 
Date: 
 
10 Dec 2010 
 
Subject: 
 
ACUTE PULMONARY HAEMODYNAMIC EFFECTS OF APELIN IN PATIENTS WITH 
PULMONARY HYPERTENSION 
 Study:Apelin PH Protocol 23-11-10 
 
 
1. Radiation Dose Assessment 
 
A radiation dose assessment for the proposed examination protocol is tabulated below. My interpretation of 
the supplied data (following discussion with Dr Lauren Brash) is that these patients are expected to have 1 Rt 
Heart Cath Procedure during a Diagnostic Coronary Angiogram from their involvement in this study.  I’ve 
used Mean recorded patient dosimetry data for Right Heart Cath procedures performed by Dr M Johnson in 
the Cath Lab. The local DRL for a diagnostic coronary angiogram is 36Gycm2 & 5.6 minutes fluoroscopy 
(3rd Quartile). 
 
The Total Research Protocol Dose is 7.8 mSv, i.e. the expected dose for x1 CA & x1 Rt Heart Cath at GJNH 
site. 
  
Radiologica
l Protocol 
Examination DAP 
(Gycm2) 
Total 
Effective Dose 
(mSv) 
(NRPB-W4) 
Additional 
Lifetime Fatal 
Cancer Risk 
Risk 
 
Normal 
 
1 CA  
 
22.1 
 
5.7 
 
1 in 3480 
 
Intermediate 
 
Expected 
 
1 CA & 1 Rt 
Heart Cath 
 
30.1 
 
7.8 
 
1 in 2560 
 
Intermediate 
 
Additional 
 
1 Rt Heart 
Cath 
 
8 
 
2.1 
 
1 in 9600 
 
Intermediate 
  
2. Risk Estimate 
2.1 mSv effective dose is equivalent to 11 months background radiation and represents an additional risk of 
lifetime fatal cancer of 1 in 9600.  In terms of comparative lifetime risk of death, it is similar to the lifetime 
risk of death from work in a service industry, and is in the Intermediate risk category for bio-medical 
research (ICRP Publication 62, 1991). 
 
A G Brennan 
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Radiation Protection Adviser 
& Consultant Medical Physicist 
 
c.c. Dr Lauren Brash 
 Dr Grant Baxter 
 Miss Lynn Dallas
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Appendix F 
Study Title: Acute Pulmonary Haemodynamic Effects of Apelin in Pulmonary Hypertension 
 
Main REC: West of Scotland REC 4       REC reference number: 11/AL/0014 
Chief Investigator: Prof. A Peacock       
                    
          
     
Event Information  
Event  Date/Time of onset Action Taken Outcome Date/time of 
resolution 
Relationship to study 
procedure 
    
None 
Terminated prematurely 
 
Unknown 
Resolved 
Resolved with sequelae 
Ongoing 
Fatal 
 
   
Not reasonably attributable 
Possibly attributable 
Reasonably attributable 
N/A 
 
 
 
Minor Event 
     
 
     
Serious Event: (Report to Chief Investigator ASAP) 
    
    Death 
    Life Threatening 
    Hospitalisation/prolongation of existing 
   
 
    Persistent/significant disability or 
incapacity 
    Congenital anomaly or birth defect 
 
 
 
Centre Principal Investigator 
  
Study Participant 
Patient No. Date of Birth Gender Date of RHC 
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Appendix F 
Concomitant  Medication (attach additional sheets if required)   
Medication name Dose Route 
   
   
   
   
   
   
   
   
 
 
Adverse Event – Details (attach additional sheets if required) 
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Appendix F 
 
Adverse Event – Details Continued… 
 
 
 
Reporting Investigator 
Name (printed) Address Contact 
number/email 
Signature Date 
     
 
Please send completed forms to the Chief Investigator via: 
 Contact: Dr Lauren Brash 
Scottish Pulmonary Vascular 
Unit 
Golden jubilee National 
Hospital 
Agamemnon Street 
Clydebank 
Glasgow 
G81 4DY 
 
 
 
 
Tel: 07738 569980 
Fax: 0141 951 5948 
Email: 
laurenbrash@nhs.net 
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